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1 Summary 
Dosage compensation (DC) in male Drosophila melanogaster flies is done through 
hypertranscription of the X chromosome. This involves the dosage compensation complex 
(DCC), a ribonucleoprotein complex of five protein subunits, Male-specific-lethal 1 (MSL1), 
MSL2, MSL3, Males-absent-on-the-first (MOF) and Maleless (MLE), and long noncoding 
RNA, RNA-on-the-X (roX), encoded by either roX1 or roX2 gene.  
DC is interlinked with the process of sex determination. A hypothesis suggests that upon 
hybridization of roX1 and roX2 RNAs, a miRNA is produced that is implicated in a feedback 
mechanism of sex determination. Different approaches were used to reproduce hybridization 
and validate putative miRNA; however, such observations could not be seen.  
As differential function of roX RNAs have been proposed, characterization of roX1 and 
roX2 RNAs in fractionated extracts were done by rt-qPCR. Long isoforms of roX, roX1-RE 
and roX2-RB, tended to be polyadenylated and enriched in the cytoplasm suggesting 
differential post-transcriptional processing and possible shuttling mechanism. A preliminary 
experiment of direct-RNA nanopore sequencing detected major parts of roX RNAs important 
for DC. With improved protocol of RNA preservation and library preparation, it may prove to 
be a potent tool to further characterize the lncRNAs and profile its isoforms. 
Additionally, a detailed study on the establishment of dosage compensation during early 
embryogenesis was done. MSL2 binding to DNA was evident 4 hours after egg laying when 
least compensation of X-linked genes is observed. Concurrent detection of MOF on the X 
chromosome signified assembly of DCC in early development. This complex was active in its 
function to acetylate H4K16. Nevertheless, accumulation of H4K16ac on the X chromosome 
proceeded in a time- and space-dependent manner, coinciding with the progression of dosage 
compensation. Specifically, genes defined as constitutive were closer to DCC binding sites, 
more acetylated, and first compensated. Meanwhile, genes characterized as developmental 
were farther from DCC binding sites, lowly acetylated, and slowly compensated.  
Zusammenfassung 
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2 Zusammenfassung 
Die Dosiskompensation bei männlichen Drosophila melanogaster Fliegen erfolgt durch 
Übertranskription des X-Chromosoms. Dies wird durch den Dosiskompensationskomplex 
(DCC) ermöglicht. Dieser Ribonukleoproteinkomplex besteht aus fünf Proteinuntereinheiten, 
Male-specific-lethal 1 (MSL1), MSL2, MSL3, Males-absent-on-the-first (MOF) und Maleless 
(MLE), und einer langen nichtkodierenden RNA, RNA-on-the-X (roX), die entweder durch das 
roX1- oder das roX2-Gen kodiert wird. 
Die Dosiskompensation ist mit dem Prozess der Geschlechtsdetermination verbunden. Die 
Hypothese, dass bei Hybridisierung von roX1- und roX2-RNAs eine miRNA erzeugt wird, die 
an einem Rückkopplungsmechanismus der Geschlechtsdetermination beteiligt ist, wurde in 
dieser Arbeit getestet. Leider konnten vorangegangene, hypothesenstützende Beobachtungen 
nicht reproduziert werden. 
Für die roX-RNAs wurde eine redundante Rolle in der Dosiskompensation sowie 
zusätzliche Funktionen außerhalb dieses Prozesses vorgeschlagen. Diese Dissertation umfasst 
die Charakterisierung von roX1- und roX2-RNAs in fraktionierten Embryoextrakten durch RT-
qPCR. Die Ergebnisse deuten auf eine differenzielle posttranskriptionale Verarbeitung der 
RNAs hin. Lange Isoformen von roX, roX1-RE und roX2-RB sind polyadenyliert. Darüber 
hinaus sind sie im Zytoplasma angereichert, was auf einen möglichen Austausch mit dem 
Nucleus hindeutet. Definierende Abschnitte der für DC wichtigen roX-RNAs wurden in einem 
explorativen Experiment durch direct-RNA nanopore Sequenzieren nachgewiesen. Mit einem 
verbesserten Protokoll zur Extraktion der RNA, sowie deren Konservation und 
Bibliotheksvorbereitung könnte es sich als wirksames Instrument zur weiteren 
Charakterisierung der langen nichtkodierenden RNA und auch in Bezug auf die Selektion der 
RNA-Isoformen erweisen. 
Zudem wurde im Rahmen dieser Arbeit eine detaillierte Studie zur Etablierung der 
Dosiskompensation während der frühen Embryogenese durchgeführt. Die Bindung von MSL2 
an DNA war bereits 4 Stunden nach der Eiablage messbar. Zu diesem Zeitpinkt ist nur eine 
geringe Dosiskompensation von X-Chromosom gekoppelten Genen vorhanden. Gleichzeitig 
ließ sich ebenfalls MOF bereits in derselben Region auf dem X-Chromosom nachweisen. Dies 
zeigte die Bildung des DCC in der frühen Embryogenese. Der Komplex war bereits aktiv und 
acetylierte H4K16. Trotzdem verlief die Akkumulation von H4K16ac auf dem X-Chromosom 
nachfolgend zeit- und positionsabhängig, übereinstimmend mit dem Fortschreiten der 
Dosiskompensation. So wurden Gene, die als konstitutiv definiert wurden und näher an DCC-
Zusammenfassung 
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Bindungsstellen lagen, stärker acetyliert und zuerst kompensiert. Als Entwicklungsgene 
definierte Gene hingegen, lagen weiter von DCC-Bindungsstellen entfernt, wurden nur 
schwach acetyliert und langsam kompensiert.  
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3 Introduction 
3.1 Drosophila melanogaster 
Drosophila, familiarly known as fruit flies, are human commensal species usually attracted 
to rotten fruits. The first reports on the use of Drosophila melanogaster (D. melanogaster) as 
a model organism emerged in the early 20th century. Due to the ease of chromosome analysis 
and the assortment of phenotypical markers available to follow crossing events, Drosophila 
proved to be a powerful organism to study genetics (1,2). Since then, D. melanogaster has 
established itself to be a versatile tool for a wide range of research from the most fundamental, 
such as molecular biology, to the most applicable, such as behavioural sciences and drug 
discovery (3). It presents simplified, robust, and expeditious variety of techniques while 
maintaining relevance to larger and more complex systems. For example, the genome editing 
tool CRISPR-Cas9 system that is first discovered as part of the prokaryotic immune system 
has been customized to the fly system extensively that nowadays there are 3699 guide RNA 
stocks combinable with 33 Cas9 or 47 UAS-dCas9 stocks available to create tissue-specific 
overexpression or knockout of genes. One of the greatest aspects of D. melanogaster is its 
detailed biology known to the scientific community and the vast adaptable methods available 
to track and manipulate it (3). Hence, it is inevitable that D. melanogaster is utilized as a model 
organism in many kinds of proof-of-principle studies.  
3.1.1 Embryogenesis 
D. melanogaster develops from a fertilized egg to an adult in a span of nine to ten days at 
a temperature of 25C. During this time, embryogenesis takes ~24 hours (hrs) to accomplish, 
after which the animal progresses through three instar larval stages, termed first (~24 hrs), 
second (~24 hrs) and third (~48 hrs). In the next pupal stage (~five days) the animal undergoes 
intense metamorphosis followed by eclosion, where adult flies emerge and are ready to close 
the circle of life, i.e. mate, within ~eight to twelve hours (Fig. 1) (3). 
The outward appearance of D. melanogaster embryo during development has been well 
described since 1970s as no special instrument other than a light microscope and a quick 5-
minute preparation to remove the chorion suffice. To this end, Bownes published a detailed 
stage-by-stage description of the first 22 hours of development, which is still widely used as a 
reference to sort embryos into stages (4). To complement the information of external 
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characteristics, corresponding internal morphological changes has been described by Foe and 
colleagues (5). 
 
Figure 1. Life cycle of Drosophila melanogaster from embryogenesis to adulthood taking 
roughly 10 days to complete. Embryo images are adapted from the Atlas of Drosophila 
Development and used with permission (10).  
Upon fertilization, maternal and paternal pronuclei merge and set off 13 nuclear cycles 
(nc) of synchronous division without cytokinesis. The nuclei are only subjected to S- and M-
phases in these first two hours after egg laying (ael; stage 1-4) (6,7). ~6000 nuclei share a 
common cytoplasm to form a syncytial blastoderm before they undergo a final division (nc 14) 
accompanied by cellularization to form a cellular blastoderm (~2.5 hrs ael; stage 5). 
Gastrulation then occurs where the three layers of endoderm, mesoderm and ectoderm arise 
Introduction 
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(~3 hrs ael; stage 6-7). For the next 4 hours (stage 8-11), the embryo elongates its germ band 
to almost double the length to prepare for the next phase of segmentation that occurs as the 
germ band retracts (~7-10 hrs ael; stage 12-13). The next phase of development consists of 
head involution and dorsal closure (~10-13 hrs ael; stage 14-15), followed by small outward 
change, but intensive internal cellular differentiation to form the various organs (~13-24 hrs 
ael; stage 16-17) (Fig. 1).  
Like many other organisms in which embryogenesis takes place ex utero, rapid 
development of D. melanogaster embryo is necessary for the survival of the animal. One 
solution to ensure sufficient resources is the deposition of maternal components into the 
developing oocyte. Maternal mRNAs, proteins, including translational machinery components, 
and nutrients are abundantly loaded and drive maturation of the egg and replication of the 
zygotic genome while it is still quiescent. It is roughly estimated that 65% of the Drosophila 
protein-coding transcriptome is supplied and post-transcriptionally regulated (7). Nonetheless, 
a transition must occur in which the maternal control on embryogenesis subsides and is 
replaced by zygotic components. This is a process termed Maternal-Zygotic-Transition (MZT) 
and includes a phenomenon named Zygotic Genome Activation (ZGA) (8,9). Although MZT 
and ZGA are gradual processes, zygotic transcription is in full gear by the time embryos reach 
gastrulation stage (~2.5 hrs ael; stage 5).  
3.1.2 Maternal-Zygotic transition 
During the initial phases of embryogenesis in which zygotic genome is still silenced, 
maternal mRNAs is tightly controlled by a set of RNA-binding proteins (RBPs). Directions 
include mRNA localization, translation efficiency, and poly(A)-tail lengths as well as mRNA 
stability, repression and degradation. This all translates to the patterning of the embryo that 
leads to its polarization required for further development. An example of a positive regulator 
is the protein Staufen. It is positively conserved and is involved in spatiotemporal control of 
maternal mRNA localization and protein production (11). 
Two processes must conspire to achieve a successful transition from maternally controlled 
to zygotically dictated development. First is maternal clearance, i.e. the removal of maternal 
instructions, which is critical as many maternally deposited components are required to drive 
early growth but detrimental for later development of embryo (12). This process relies on 
tightly regulated activation of miRNA-mediated gene silencing, whereby RNA-binding 
proteins (RBPs) acting as translational repressor cooperatively invoke maternally and 
zygotically directed mRNA decay (13). Maternally directed decay is orchestrated by Smaug 
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(Smg), Brain tumor (Brat), and Pumilio (Pum). Their transcripts are maternally deposited and 
translated upon activation of the unfertilized egg (13). They initiate decay by recruiting 
deadenylation complexes and conserved degradation machinery to a subset of maternal 
transcripts (7). Pum and Brat also regulate zygotically directed mRNA decay, however, this 
phase accordingly relies on some zygotic transcription to produce a particular cluster of 
miRNA (miR-309) that instructs removal of maternal mRNAs specifically through the 3’ UTR 
targeting (14). All in all, 25% and 35% of cleared transcripts are exclusive targets of the 
maternal and zygotic machineries, respectively, while 40% transcripts are cleared by both 
acting in concert (9,12).  
The second determinant of a successful hand-over from maternal to zygotic control of 
development is the establishment of zygotic transcriptome (15). Two waves of ZGA set up its 
full activity, the minor and major waves (8,9). The minor wave of transcription occurs during 
the rapid nuclear replication of early embryos from nc 8 on. A small subset of short intronless 
genes of Drosophila are biasedly expressed during the limited time between each of the nuclear 
cycles (7,16). The expression profiles of these genes are thought to be driven by two factors, 
nuclear to cytoplasmic ratio (N:C) and time elapsed since fertilization (17,18). As nuclei 
amplify exponentially without an increase in embryo volume, the N:C ratio progressively 
changes. Experimentation with increased and decreased ratios suggest that with each division, 
maternal components are titrated down thereby relieving repression on transcriptional activity 
of target genes (19). Concurrently, N:C-independent genes rely on the maternal clock that times 
translation of their regulator. One such example is the maternally deposited and master 
regulator of ZGA zelda (zld). The transcription factor (TF) Zld is translated at nc 8, after which 
zygotic expression is observed for a small number of genes, whose enhancers and promoters 
are highly enriched with Zld binding sites (20-22). Early Zld binding increases chromatin 
accessibility specifically for Zld-dependent genes and promotes recruitment of Pol II (20). 
Interestingly, this includes components of the zygotic RNA degradation pathways, i.e. miR-
309, thereby linking ZGA with events of zygotically directed maternal clearance (23). 
Although additional Zld binding sites are found on other regulatory regions of zygotic genes, 
their expression does not commence until the major wave of transcription is initiated pointing 
towards a concentration-dependent activation (7). 
Several changes occur that signify the onset of the major wave of ZGA. In addition to Zld-
dependent expression of genes, Zld appears to facilitate association of additional transcription 
and pioneering factors to maintain an open chromatin state. Among others, the GAGA Factor 
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(GAF) encoded by Trithorax-like (Trl) has been reported to cooperate with Zld in potentiating 
the major wave transcription (24). GAF maintains nucleosome-free regions and recruits Pol II 
to promoters that are both dependent and independent of Zld (25,26). Correspondingly, Pol II 
is majorly recruited at nc 13 to many Transcription Start Sites (TSSs). Nevertheless, their 
activity is kept poised to repress inappropriate expression of developmental genes yet prime 
them for expression at later stages (20,24,26,27). Accordingly, chromatin architecture that is 
largely loose and unstructured before ZGA undergoes progressive remodelling and maturation 
from being relatively decondensed with equal probability of contact across the genome to 
acquiring short-range topologically associating domain (TAD) structures and long-distance 
compartmentalization (28-30). Once established, these chromatin conformation and TAD 
boundaries are retained throughout development and in adulthood. Remarkably, regions 
consisting of house-keeping genes show pre-disposition for these boundaries even earlier and 
independent of transcription, although gene expression is still needed to refine organization 
(28). At the onset of nc 14, cellularization of nuclei and prolonged cell cycle length permit the 
introduction of a G2 gap phase, alleviating the disruptive forces of DNA replication on 
transcription (7). And so, transcription of the zygotic genome trickles in to replace maternal 
control over development.  
The interplay of time and space coordination between destabilization of maternal mRNA 
and zygotic transcription of early developmental genes designates anteroposterior and 
dorsoventral axes necessary for proper patterning of the embryo. Indeed, this process involves 
the earliest regulator of mRNA decay, Smg, and the master regulator of ZGA, Zld, through 
their function in regulating a plethora of patterning genes (31-35). 
3.1.3 Sex determination 
In D. melanogaster, as is in H. sapiens, males are heterogametic for the sex chromosomes 
X and Y, whereas females are homogametic, XX. Unlike in human, however, sex 
determination is done early in embryogenesis and does not rely on the presence of a Y 
chromosome but rather on the number of X chromosome. With this distinction in mind, a 
mechanism to “count” the X chromosome must occur to determine sex specificity (3). Counting 
of X relies on the X-linked sex regulator gene, Sex-lethal (Sxl). In females, the double dose of 
X allows for enough SXL translation upon ZGA. In a positive feedback loop, SXL regulates 
its own alternative splicing to further stabilize female-specific transcripts (36), as well as 
splicing of additional factors involved in strengthening the female-specific gene expression, 
morphology, and behaviour, i.e. transformer (tra), doublesex (dsx) and fruitless (fru) (Fig. 2).  
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Measurable Sxl transcripts can be categorized into three classes: early-female, late-female, 
and late-male specific. The early promoter of Sxl, also known as the “establishment promoter” 
(SxlPe), transiently expresses early-female transcripts. This burst of expression commences at 
nc 12, when minor wave of ZGA allows X-linked signal elements (XSE), a group of four X-
coded proteins (Ascute, sisA, Runt, Unpaired), to reach a threshold concentration to preclude 
a maternal Sxl negative regulator, Groucho (Gro), and activate SxlPe specifically in females 
(36-39). A switch in promoter choice occurs at the cellular blastoderm stage (~2.5 hrs), in 
parallel with the major wave of ZGA chain of events. The late promoter of Sxl, termed the 
“maintenance promoter” (SxlPm), produces Sxl mRNA that are spliced into either male- or 
female-specific isoforms. The male isoform includes exon 3, which contains a STOP codon, 
and therefore is translated into a truncated, non-functional protein (36). On the contrary, exon 
3 is spliced out in the female isoform, allowing for functional production of Sxl (36) (Fig. 2). 
 
Figure 2. SXL is the master regulator of sex determination and regulates many genes to 
establish a female phenotype, and its absence drives the male development.  
Sxl contains two highly conserved RNA-binding domains, which preferentially target long 
stretches of poly(U) interrupted with guanine (36). The Sxl pre-mRNA itself has such 
sequences upstream and downstream of exon 3, the male-specific exon, and interaction of 
functional Sxl with components of the splicing machinery at these sites ensures exon 3 
skipping. In early female embryo, Sxl produced from SxlPe is sufficient to trigger the loop and 
the “late” form of female Sxl maintains a positive autoregulatory splicing control on Sxl 
expressed from the SxlPm, locking it ON. This regulation is absent in males due to lack of 
functional Sxl and so only noncoding Sxl mRNA with a premature STOP codon is ever 
produced (36,40). Once activated, Sxl initiates the female-determining program (Fig. 2). It first 
rescues Tra pre-mRNA, whose default splicing pattern encodes a short non-functional protein 
(41,42). Tra functions to strengthen the female phenotype by prompting female-specific 
splicing of Dsx (DsxF) and Fru (FruF) pre-mRNAs (42) (Fig. 2). DsxF is involved in female 
organ development and tissue differentiation, whereas FruF splicing results in a premature 
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STOP codon and accordingly non-functional protein (43-45). Concurrently, the absence of Tra 
in males leads to default splicing of Dsx (DsxM) and Fru (FruM), where DsxM invokes male 
morphology and in concert with FruM determines male courtship behaviour in adults (43-46) 
(Fig. 2). Sxl sits at the top of the sex regulatory chain and its importance is clearly demonstrated 
by female-specific lethality upon loss of Sxl in XX animals and male-specific lethality upon 
inappropriate Sxl expression in XY (47,48). 
3.1.4 Interlink of sex determination and dosage compensation pathways 
Once sex has been determined, specific programs of development are initiated. A challenge 
unique to males is their state of heterogamy. As genes on the X are equally important for both 
sexes, dosage compensation of the single X is essential in male animals. The directive to initiate 
this mechanism is the outcome of the sex determination process. Therefore, as a link between 
the two pathways, Sxl orchestrates the expression of male-specific-lethal 2 (msl-2), the core 
component of dosage compensation, multifacetedly (Fig. 2). The msl-2 mRNA contains several 
putative Sxl binding sites in its 5’ and 3’ untranslated region (UTR), two of which are found 
within a 5’ intron (49-52). In the nucleus, binding of Sxl to the 5’ UTR of msl-2 pre-mRNA 
ensures a specific splicing event in which the intron is retained (49,51,52). Once exported to 
the cytoplasm, the retained intron serves as a landing platform for Sxl. In combination with Sxl 
binding at 3’UTR, translational repression is exerted by steric inhibition of ribosomal initiation 
complex recruitment and start codon recognition (36,50). As females express fully functional 
SXL, this leak-proof repression continuously occurs. However, the male form of SXL is 
truncated therefore non-functional and so MSL2 is expressed at steady state and dosage 
compensation is maintained in males (50,53).  
3.2 Dosage Compensation  
Dosage compensation (DC) is a mechanism that has evolved to ensure balanced expression 
of sex-chromosomal gene products. Many species that are sexually dimorphic have adapted 
different approaches to address this imbalance, from the inactivation of one of two female Xs 
in H. sapiens, to halving the X expression in hermaphrodites of C. elegans (47). D. 
melanogaster achieves this balance by approximately increasing the male X expression two-
fold (47,48). In cases where DC fails, male-specific lethality is observed and conversely, when 
DC is induced in females, low viability, sterility and developmental delay is described (54-56). 
Dosage Compensation 
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3.2.1 Dosage Compensation Complex and its components 
Dosage compensation in flies is carried out by a complex termed Male-Specific-Lethal 
(MSL) or DC complex (Fig. 3). The first members of DCC discovered in 1980 were msl-1, 
msl-2 and mle (54,57). A fourth gene, msl-3, was added in 1981 (58). And the final protein 
member of the complex, males-absent-on-the-first (mof) was linked to DCC much later in 1997 
(59). Last but not least, a long non-coding RNA, RNA-on-the-X (roX) RNA, completes DCC 
(60). This ribonucleoprotein complex decorates the single male X chromosome exclusively and 
enriches it with acetylation at lysine 16 of histone H4 (H4K16ac) (61). The chromosome-wide 
histone modification enhances chromatin accessibility and supports hyper-transcription, 
thereby, increasing the production of X-linked genes (62,63) (Fig. 3). 
 
Figure 3. Dosage compensation complex targeting and spreading mechanism.  
MSL2 is the only male-specific protein and is the decisive factor of DC. It also functions 
as an E3 ubiquitin ligase, shown to ubiquitinate itself as well as other Msl proteins to target 
them for degradation as means of maintaining stoichiometry (64-66). MSL2 interaction with 
the rest of the complex is mediated by MSL1, the scaffold (67). MSL1 and MSL2 make a core, 
whose interaction was revealed in a co-immunoprecipitation assay and its structure 
subsequently resolved (56,64). Whereas the MSL1 N-terminus provides MSL2 interaction, its 
C-terminus carry binding sites for MSL3 and MOF (64,68,69). MSL3 bears a chromodomain 
(CD) that can recognize methylated histone H3 at lysine 36 (H3K36me3), a mark associated 
with active transcription (70-72). An observation of male X-specificity of H4K16ac led to the 
discovery of MOF, the histone acetyltransferase, that works to ease transcription repression by 
chromatin (59,73-75). MLE is an RNA helicase with two double-stranded RNA binding motifs 
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specific for single-stranded RNA or DNA (76,77). It unwinds roX RNA to permit incorporation 
into DCC in an ATP-dependent manner (78,79). 
3.2.2 Assembly and targeting of DCC 
DCC is a solution to an issue at hand, namely X imbalance. Naturally, very specific 
mechanism had to be put in place so that an increase in gene expression only effects those that 
lacked in dose. Therefore, fine tuning of targeting by DCC is as necessary as its assembly. 
The current state of literature agrees on an assembly of DCC centered around the 
transcription of roX RNA in a stepwise manner (80) (Fig. 3). As roX is being produced, MLE 
comes in and remodels it to reveal MSL2 binding sites (79,81). The core complex of 
MSL1/MSL2 joins in, bringing along MSL3 and MOF (64). MSL2’s CXC and proline/basic-
residue-rich domains equips DCC with targeted direct DNA binding to X-enriched sites termed 
chromosomal entry sites (CES) or more recently high affinity sites (HAS) (82-87). This binding 
occurs favourably in vitro, however, its placement in vivo requires the cooperation of a zinc-
finger protein, chromatin-linked adaptor for MSL proteins (CLAMP), to compete with 
deposition of nucleosomes on sites termed MSL response elements (MREs) (88,89). 
Interestingly, two of these enhancer elements are within roX genes, strengthening the theory 
that roX genes serve as nucleation sites of the complex (82,90). Of the HAS are a subset found 
to be pioneering sites on the X (PionX) defined by refined DNA sequence and shape (91) (Fig. 
3). Once bound to these sites, DCC spreads along the chromosome by various mechanisms. 
First, H3K36me3 recognition by MSL3 allows spreading of DCC to neighbouring genes that 
are active and require hyper-transcription (70-72). Second, established 3D chromosomal 
structure aids long-range interaction between active compartments that enhances spreading 
DCC (92). Third, by yet an unknown mechanism, roX RNA promotes efficient spreading along 
the chromosome, as evidenced by disrupted H4K16ac pattern in mutant males (93,94). A 
mapping of roX RNA-chromatin interaction has been published, and interestingly, among a 
majority of common roX binding to the X chromosome, there are evidently cell type specific 
interactions that is reflected in gene expression (95).  
3.2.3 Mechanism of dosage compensation 
Although many steps can be customized to increase expression, DCC appears to operate 
at the transcriptional level. Studies on Pol II in the context of DC suggests that enhancing 
recruitment of the transcription machineries led to a 1.2-fold increase in Pol II activity at 
promoters of X-linked hyperacetylated genes (96-99). Concurrently, multiple reports provided 
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evidence for a different mechanism showing that DCC improves transcriptional output by 
facilitating the progression of Pol II through a direct interaction between MSL1 and SPT5, a 
transcription elongation factor (100,101). Through improved genome-wide studies, 5’ paused 
Pol II is detected to be equally present when normalized to the gene dose, although the 
elongating Pol II phosphorylated at serine 2 (Ser2P) is evidently increased over X-linked gene 
bodies (102,103). This suggests that the key rate-limiting step is the release of paused Pol II, 
which is overcome by the change in chromatin landscape facilitated by DCC. The 3’-biased 
H4K16ac, a histone modification that has been shown to decrease chromatin compaction, 
decreases steric hindrance for a transcribing Pol II, thereby allowing a coordinated increase of 
X-linked transcription (73,104-106). And so, with an increase in H4K16ac, an increase in Pol 
II-Ser2P follows. 
3.2.4 During development: establishment of dosage compensation  
As has been reviewed earlier, dosage compensation is initiated upon conclusion of being 
“male” in the sex determination pathway. Whereas MSL2 is stably expressed only upon ZGA, 
other members of DCC, i.e. MSL1, MSL3, MOF, and MLE are maternally contributed (Fig. 
4). The assembly of DCC is attained and thereby single X targeting is feasible. Nonetheless, 
there is a disparity between onset of transcription and detection of DCC by means of 
immunofluorescence, which due to limited resolution may not show if MSLs are bound to HAS 
but have not spread onto active genes. Nuclear localization of MSLs is first observed at stage 
6 of blastoderm (~3 hrs ael) and accumulation onto X territories only occurs at stage 9, about 
an hour later (107,108) (Fig. 4). As some X-linked genes are needed for development during 
this time, an MSL-independent mechanism is thought to persist to ensure that sex chromosome 
dose difference does not translate into disastrous outcome. An attractive candidate of such 
regulator turns out to be Sxl as many genes that harbor more than 3 Sxl binding sites in their 
3’ UTRs are X-linked (53,56,109,110). Indeed, several mRNAs of developmental regulators 
encoded on the X are present at equal levels in male and female embryos present in this time 
window (22).  
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Figure 4. Summarized data of MSL protein and roX RNA expression in early embryogenesis. 
3.3 lncRNA in Dosage Compensation 
In 1972, Susumo Ohno coined the term “junk DNA” to sequences with “the importance 
of doing nothing” (111), a misnomer that has since been disproven in many studies across many 
different species (112,113). Although only a small percentage of the genome represents 
protein-coding sequences, the larger non-coding region is hardly “junk” and is as critical for 
the maintenance of life. As a matter of fact, these sequences that may seem to be repetitive 
elements enrich various organisms with adaptive tools in the process of evolution and 
highlights the dynamicity of genomes (113,114).  
Annotation of non-coding elements of genomes has since revealed many hidden 
features that can act as switches and signals for protein-coding genes. One such class of 
regulatory elements encode for long non-coding RNA (lncRNA), a stretch of more than 200 
nucleotides, that can modulate processes from chromatin organization all the way to post-
translational modification (115). 
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3.3.1 roX RNA in dosage compensation 
As the name suggests, roX RNA is encoded on the X chromosome and can be produced 
from either roX1 or roX2 gene. They were first discovered in studies of the Drosophila brain 
and were reported back-to-back in 1997 (116,117). roX RNA colocalization with MSLs on the 
X chromosome has been shown in various tissues through assorted methods that range from 
the most conventional, i.e. in-situ hybridization and immunostaining (116,118), to ones with 
high resolution and high-throughput, i.e. Chromatin Isolation by RNA purification sequencing 
(ChIRP-seq (78,119)), Chromatin-associated RNA sequencing (ChAR-seq (120)), and RNA-
DamID (95). To elucidate whether the targeting of X chromosome is in part due to the X-
linkage of the roX genes, autosomal integration of either roX genes was performed and showed 
that roX RNA is able to find the X chromosome (116,121,122). As additional roX and MSL 
spreading nearby the insertion site can be seen, it reiterates that roX RNA can work in trans to 
specifically target the X chromosome and in cis to spread DCC along the X chromosome 
(121,122). X chromosome composition wins over source of roX in the X targeting. 
Early genetic studies on single and double mutants of roX RNA also reveal a functional 
redundancy within dosage compensation. Excision mutants of roX1 did not affect X 
localization of MSLs and viability, whereas early design of roX2 deletion did not disrupt MSL 
binding pattern but lowered viability through collateral deletion of neighbouring genes 
(116,118,121). Nevertheless, this indicates that only one of either roX RNAs is required and/or 
sufficient for proper DC. And so justifiably, as soon as both roX genes were altered, male 
double mutants do not survive past the third larval instar stage reminiscent of male-specific 
lethality, although some escaper males were detected (118,121,122). Examination of MSL 
distribution and transcriptional effect in these roX mutants reveal that the primary cause of 
lethality is the mislocalization of MSLs to ectopic sites on chromocenters and autosomes (121-
123) that in turn fail to activate dosage compensation of the X (124). 
Using a combination of deletion analysis and fly genetics, Stuckenholz, Park, Kelley, 
and colleagues identified the minimal requirement for their function to short conserved 
sequences termed roX boxes, GUUNUACG, in the 3’ end of roX RNAs that are prevalent 
within stem-loops (SLs) (93,125-127) (Fig. 5). The structure, in addition to sequence, of these 
stem-loops coined SLroX1 and SLroX2 prove to be targets of MSL2 and MLE binding, 
necessary for the assembly of DCC (78,79). This specific targeting occurs in an ATP-dependent 
manner whereby the remodeling of roX RNA by MLE is required (78,79,128). Although they 
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seem to exhibit functional redundancy, interesting differences exist as outlined in the next two 
subchapters. 
3.3.2 roX RNAs and their isoforms 
roX1 and roX2 RNAs exhibit similar characteristics, in addition to their X-
chromosomal localization. Both RNAs only carry small open reading frames (ORFs), whereby 
prediction yields 59 and 45 amino acids, respectively (117). Their transcripts undergo post-
transcriptional processing, including polyadenylation and alternative splicing, albeit lack of 
reports on nuclear export (117,129).  
 
Figure 5. roX RNAs and their isoforms. roX1 has five isoforms, while roX2 has six. A predicted 
secondary structure has been hypothesized only for roX2; nonetheless, the main interacting 
stem loop structures have been mapped for both RNAs and consensus roX box sequence 
determined. 
Interestingly, that is where the similarities end. roX1 is a gene of length ~5400 nt (116), 
and five isoforms (roX1-RA to -RE), all containing roX boxes and roughly ~3700 nt in size, 
have been annotated (Fig. 5). The roX2 gene is smaller than its counterpart with a sequence of 
~1300 nt (117). And contrarily, roX2 undergoes more extensive splicing to produce six 
isoforms (roX2-RA to -RF), also all containing roX boxes, that are largely of ~600 nt in size 
(Fig. 5). Although the significance and relevance of each individual roX isoforms is poorly 
understood, it has been shown that alternative splicing is crucial in DC as a plethora of roX2 
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isoforms was required to keep a steady-state level of RNA and an accumulation of MSL 
complex on the X chromosome (129). 
Simple alignment of their primary sequence reveals that there is very low conservation 
between the two RNAs. A recent evolutionary study in diverse Drosophilid species across 40 
million years employed a strategy where synteny, microhomology, and secondary structures 
are integrated to identify orthologs of roX1 and roX2 RNA. The findings reiterate the relevance 
of conserved structure over primary sequence homology as roX orthologs from distantly related 
species are functional in dosage compensation and are able to rescue failure to compensate 
across different species (114). 
3.3.3 Expression of roX RNAs during development 
The first publications on roX RNAs have already reported distinctions in profile of 
expression (Fig. 4). Puncta of roX1 in nuclei are visible in both sexes during blastoderm 
formation (as early as 2 hrs ael) with the strongest signal being in neuronal cells (116). Upon 
germband retraction (~10 hrs ael), roX1 diminishes specifically in females and its male 
specificity is evident by the time epidermal segmentation starts (~13 hrs ael) (130). By contrast, 
roX2 transcription does not start until stomodeum invagination commences (~6 hrs ael) and its 
signal is much weaker than that of roX1 (130). Nevertheless, it does so immediately in a male-
specific manner. By the time male embryos reach the third instar larval stage, relative level of 
roX1 and roX2 is equalized (130). Two studies have described developmental transcriptome 
during embryogenesis and provided data for re-analysis (22,131). One of the studies looked 
into very early stages of synchronous rapid nuclei division, during which roX RNA expression 
is insignificant (22). The second study examined 2-hour window transcriptome of developing 
embryos from 0 to 24-hour ael; however, collection of mixed sex was used (131). Nevertheless, 
it recapitulates earlier reports that roX1 RNA is transcribed first followed by roX2 RNA 
transcription roughly a few hours later (131). 
The peculiarities in expression profile impart a difference in early phenotype of single 
roX mutants. Although no delay in development is seen with either single mutants (116,121), 
roX1 mutants suspend its MSL localization to the X chromosome until roX2 is expressed (130). 
roX2 mutants, on the other hand, is highly dependent on maternally deposited MLE to stabilize 
early roX1 transcripts (130). To note, developmental delay is observed in mutants only 
expressing any one isoform of roX2 at endogenous level that can partly be rescued through 
overexpression (129). This highlights the importance of steady state expression and alternative 
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splicing of a plethora of roX RNA; nonetheless, synthetic lethality of roX1 and roX2 
demonstrate their redundant role in dosage compensation. 
3.3.4 RNA and miRNA biogenesis 
Another non-coding regulatory elements that have gained interest in recent decades are 
microRNA (miRNA). It belongs to the class of small non-coding RNA due to its size of only 
~22 nt. Unlike lncRNA, miRNA tend to specifically regulate gene expression at the post-
translational level by binding to the 3’ UTR of their target mRNA. The base pairing of miRNA 
induces gene silencing by inhibiting further protein production (132,133). To date, there are 
258 Drosophila miRNAs annotated and reported in the latest release of miRNA database 
(miRBase) that are implicated in various biological processes ranging from germline 
development to neuronal development (134). 
miRNA is the final product of many steps of RNA maturation. Upon regulated 
transcription by RNA Polymerase II (Pol II), the long primary miRNA (pri-miRNA) transcript 
typically of size ~ 1 kb is processed to unearth the miRNA seed sequence that is embedded 
within a hairpin structure. To commence, a Microprocessor complex containing Drosha, a 
nuclear RNase III, crops a ~65 nt SLs out of the capped and polyadenylated pri-miRNA (132). 
Interestingly, the efficiency of this process can be altered by single nucleotide polymorphisms 
residing in the miRNA precursors (133). The resultant pre-miRNA is then exported into the 
cytoplasm for further processing by Dicer-1 (DCR1) to create an RNA duplex (132). Once the 
RNA duplex is loaded onto Argonaute 1 (AGO1) protein, an effector complex called RNA-
induced Silencing Complex (RISC) is formed. Maturation of RISC is finalized with the 
unwinding and cleavage of the RNA duplex, and depending on strand selection, the guide 
strand is stabilized whilst the passenger degraded (132). At all stages from transcription to 
maturation, regulation of miRNA biogenesis occurs by means of processing, stability, feedback 
loops and modification of the RNA as well as proteins involved in the process (133). 
The highly stabilized and mature miRNA-induced RISC complex (miRISC) scans the 
cytoplasm for complementary mRNA targets, where the seed sequence is of importance and 
confer specificity. Association of miRISC with mRNA induces gene silencing in two ways. 
The immediate response of miRISC:mRNA interaction is the inhibition of cap recognition of 
the eukaryotic initiation factor 4E (eIF4E). This leads to hindrance of the eIF4F complex 
assembly, of which eIF4E and eIF4G are subunits, at mRNA caps (133). eIF4F is required to 
recruit the pre-initiation complex and is therefore important for cap-dependent translation 
(135). The binding has also been shown to induce the disassembly of existing eIF4F complex 
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by releasing eIF4E and eIF4G from target mRNAs (136). Additionally, miRISC association 
prompts target mRNA decay. It recruits deadenylation complexes, PAN2-PAN3 and CCR4-
NOT, which trim the poly(A) tail of the mRNA. The deadenylated mRNA then undergoes 
decapping, for which the enzyme Dcp1 is responsible for. Finally, deadenylated and decapped 
mRNA are degraded by a 5’-to-3’ exoribonuclease (XRN1).  
The miRNA-induced gene silencing is just another mechanism widely used in various 
organisms to maintain the steady-state equilibrium as well as to carry out responses to various 
stimuli, including but not limited to development. 
3.4 Chromatin 
Even the smallest and simplest organism has a genome longer in length than it can contain, 
necessitating the packaging of genetic information. Whereas this is done by supercoiling in 
prokaryotes, eukaryotes do so by packing it into structures called chromatin. The concept of 
chromatin was formed by cytologists and biochemists in the late 19th century (137,138). 
Although it was largely neglected in the first half of the 20th century, interests re-emerged with 
newfound discovery in genetics, specifically with the revelation of the polytene chromosome 
in Drosophila (139,140). Nowadays, it is irrefutable that chromatin biology is as important as 
the underlying blueprint of life. Every cell of an organism carries the same genetic code, yet 
these very same stretches of four different nucleotides give rise to many different types of cells. 
And so many great strides have been undertaken to better understand its role and regulation.  
3.4.1 Chromatin structure and organization 
The most fundamental unit of chromatin is the nucleosome, which consists of ~147 bp 
negatively charged DNA winding 1.65 turns around a positively charged histone protein core 
in a left-handed superhelical manner (141-143) (Fig. 6). The globular histone core is made up 
of pairs of four histones (H2A, H2B, H3 and H4), each having highly basic tails that protrude 
outward (141,144,145) (Fig. 6). The entire nucleosome structure is strengthened by 
histone/histone as well as histone/DNA electrostatic interactions (142,146), and therefore 
confers a physical barrier for any protein binding and processivity that require “reading” of the 
underlying genetic blueprint. Linker region of DNA bridges neighbouring nucleosomes, 
spaced on average ~200 bp apart, and is associated with the linker histone, H1 (147,148). 
Histone H1 interaction with the histone core around DNA entry and exit sites further stabilizes 
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the 10-nm nucleosomal array (“beads on a string” (149)) and allows its arrangement into 
higher-order architecture (148,150,151).  
 
Figure 6. Architecture of the nucleosome core particle. Face and top view of the nucleosome 
structure upon a 90C turn. Image is adapted from the “Post-Translational Modifications of 
Histones that Influence Nucleosome Dynamics” and used with permission (156). 
Under low salt condition in vitro, nucleosome fibers fold into rods of 30-nm in diameter. 
In vivo studies, however, favour a more irregular model in which the 10-nm array can 
interdigitate as assisted by cellular cations into globular structures (152). This ensures a degree 
of dynamicity and accessibility allowing for the formation of TADs and 3D loop structures 
(152,153). Distant promoters and enhancers can be brought together into active chromatin 
loops to elicit regulation, e.g. Zelda-dependent transcription, and inactive loops congregate co-
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regulated genes to silence them simultaneously, e.g. repressive Polycomb domain (29). Also 
responsible for the structuring of the chromatin as such are architectural proteins, such as 
mediator, cohesins and insulators, and potentially non-coding RNAs, which are all crucial for 
determining gene regulation and henceforth cell identity (154,155).  
3.4.2 Histone post-transcriptional modifications (PTMs) 
The degree of nucleosomal packing determines accessibility of genes and regulatory 
elements and therefore augments additional possibilities in refining gene regulation. This 
property is partly imparted by the largely unstructured and flexible C- and N-terminal tails of 
histones that carry more than 60 sites at which many types of PTMs can take place, the most 
common ones being acetylation, methylation, phosphorylation, and ubiquitination of residues 
arginine (R), lysine (K), serines (s), and threonines (T) (144,145,157,158). To note, limited 
histone core modification also exists (159). PTMs of the histone tails alter interactions between 
nucleosomes, DNA/histones, as well as the binding of chaperones, chromatin remodellers, and 
transcription factors. Deciphering the histone code has led to some modifications being 
associated with loosening, i.e. acetylation of H3/H4, and others tightening the chromatin 
compaction, i.e. methylation of H3K9/H3K27 (160-162). Moreover, combinatorial 
modifications can in some cases trump over individual ones (145,163)). Interestingly, PTMs 
are not completely independent of each other as deposition or removal of one can promote or 
inhibit the deposition or removal of another (162,164).  
Regulation of PTMs involve a collection of histone modifiers that can be classified as 
writers, readers or erasers. Writers deposit, erasers remove, and readers recognize to elicit 
downstream effectors such as other modifiers and remodelling enzymes. Activity of histone 
modifiers is highly specific, i.e. it usually involves a certain modification of a specific amino 
acid residue (144,161,164). To add another layer of switch regulation, writers, readers and 
erasers are tightly controlled. 
3.4.3 H4K16ac and H3K36me3 in dosage compensation 
Naturally, chromatin structure and its compactness influence all stages of transcription 
from initiation to pre-mRNA processing. Histone acetylation is by and large associated with 
active transcription, but in the context of dosage compensation, male-specific H4K16ac is of 
importance. Acetylation of H4K16 abolishes folding of nucleosomal arrays (105). Indeed, 
contact was mapped between the basic patch of H4 N-terminus, i.e. residues K16 to R23, and 
the acidic patch surface of H2A/H2B dimer of a close-by nucleosome and this looping of the 
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histone tail is critical for chromatin folding (142,165). H4K16ac alters the net charge, 
weakening inter-/intra-nucleosomal interaction to confer easier displacement of nucleosomes 
(166-168). In the Drosophila, H4K16ac is deposited by DCC’s HAT, MOF. The X-specific 
recruitment of MOF is imparted by MSL2, but its targeting towards active genes is thought to 
be afforded by DCC’s PTM reader, MSL3. CD of MSL3 reads trimethylated H3K36, a 
signature of active transcription (70-72). The third methyl group is deposited by a histone 
methyltransferase (HMT), Set2, which directly interacts with the elongating Pol II, Pol II-
Ser2P, as it travels across the gene body (169,170). Interestingly, H3K36me3 works to 
antagonize HATs by recruiting histone deacetylases (HDACs) to establish a hypoacetylated 
environment and prevent spurious intragenic transcription (171-173). 
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4 Aims 
While it has been shown that the long non-coding roX RNA is essential for dosage 
compensation in fruit flies, the exact mechanism remains to be elucidated. Preliminary 
experiments by Sylvain Maenner suggest the hybridization of roX1 and roX2 RNAs leads to 
the production of a miRNA that targets Sxl. Biochemical analysis of roX1 and roX2 
hybridization and cellular analysis of miRNA production were carried out to explore if roX 
RNAs are implicated in such a feedback mechanism to reinforce the sex determination.  
Furthermore, to monitor the establishment of dosage compensation by the Dosage 
Compensation Complex (DCC) during embryonic development, transcriptome analyses of 
single-embryos were done concurrently with chromatin immunoprecipitation of MNase-
digested chromatin coupled to next-generation sequencing for several DCC subunits, MSL2, 
MOF, MSL3, and MLE, as well as histone marks, H3K36me3 and H4K16ac. Genome-wide 
distribution profiles were correlated to tease out the characteristics of DCC targeting to high-
affinity sites (HAS) and spreading on the male X chromosome. Datasets obtained from 
embryos and cell lines (Cl.8 and S2) enabled the comparison of HAS definitions important for 
targeting. 
As both roX1 and roX2 RNAs are transcribed into different isoforms, quantitative RT-PCR 
was used to dissect their expression profiles in nuclear and cytoplasmic fractions of embryonic 
extracts, as well as cell lines with different roX RNA expressions. Finally, a new direct-RNA 
sequencing method using the Nanopore technology was tested. 
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5 Materials and Methods 
5.1 Materials 
5.1.1 Chemicals 
Acetic Acid (CLN); Adenosine Triphosphate (ATP, Sigma); Agarose (Bio & Sell); 
Ammonium Sulfate (NH4SO2, Merck Millipore); Ampicillin (Carl Roth); AMPure XP DNA 
beads (Beckman Coulter); Agencourt RNAclean XP beads (Beckman Coulter); Amylose resin 
(Biolabs); Bovine Serum Albumin (BSA, Sigma); Bradford (Bio-Rad); Bromophenol blue 
(Sigma); Chloroform (NeoLab); cOmplete Protease inhibitor (PIC, absource); Coomassie Blue 
G250 (Serva); DAPI (Invitrogen); DMSO (Sigma); DTT (Roth); EDTA (Diagonal); EGTA 
(Carl Roth); Ethanol (VWR); Fetal Calf Serum (FCS, Sigma); Glycerol (VWR); Glycine 
(VWR); Heparin (Sigma); Hepes (Serva); n-heptane (Merck Millipore); Insulin (Sigma); IPTG 
(Carl Roth); KCl (VWR); Maltose (Sigma); 2-Mercaptoethanol (Sigma); Methanol (CLN); 
MgCl2 (VWR); NaCl (Serva); Normal Donkey Serum (NDS, Merck Millipore); NP-40 
(Sigma); Penicillin/Streptavidin (life technologies); 16% paraformaldehyde, methanol-free 
(PFA, life technologies); 37% PFA (Merck Millipore); Phenylmethylsulfonylfluoride (PMSF, 
Genaxxon); Phenol:Chloroform:Isoamyl-alcohol (Invitrogen); 2-Propanol (Sigma); 
Schneider’s Drosophila Medium (life technologies); Sepharose protein A and G beads 
(Helmholtz Centre Munich, E. Kremmer); Shields and Sang M3 medium (Sigma); Sodium 
Acetate (Sigma); Sodium Azide (Merck); Sodium deoxycholate (Sigma); Sodium dodecyl 
sulfate (SDS, Serva); 6-14% Sodium Hypochlorite (Merck Millipore); Sodium metabisulfite 
(NaMBS); Sucrose (VWR); Tris (Diagonal); Triton X-100 (Sigma); Tween-20 (Sigma); tRNA 
(life technologies); Urea (AppliChem); VECTASHIELD (Vector Laboratories) 
5.1.2 Enzymes, markers, and kits  
100 bp and 1 kb DNA markers (NEB); DNA 1000/HS Kit (Agilent); Fast SYBR Green 
Master Mix (Applied Biosciences); MEGAscript T7 Transcription Kit (Thermo Fischer 
Scientific); MNase (Sigma); NucleoSpin Plasmid Mini Kit (Macherey-Nagel); NucleoSpin Gel 
and PCR Clean-up kit (Macherey-Nagel); Poly(A) Polymerase (NEB); Proteinase K (Qiagen); 
Restriction Enzymes (NEB); RNA Pico Kit (Agilent); RNase A (Sigma); RNase H (NEB); 
RNAsin (Promega); RNeasy Kit (Qiagen); rRNA Depletion Kit (NEB); SuperScript III First 
Strand Synthesis (Thermo Fischer Scientific); Qubit dsDNA HS assay kit (life technologies); 
Triple Colour Protein Standard III (Serva); TURBO DNase I (Sigma) 
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5.1.3 Antibodies 
Table 1: Primary antibodies 
Antigen Species Type Application Source 
DCR2 rabbit polyclonal WB 1:250 Abcam, Cat. No. ab4732 
GFP rabbit polyclonal IF 1:2000 ChromoTek, Cat. No. 029762 
H3K36me3 rabbit polyclonal ChIP 2 L Abcam, Cat No. ab9050 
H4K16ac rabbit polyclonal ChIP 2 L Abcam, Cat No. ab109463 
H4K16ac rabbit polyclonal 
ChIP 
IF 
2 L 
1:100 
Merck Millipore,  
Cat No. 07-329 
lamin mouse monoclonal WB 1:1000 H. Saumweber 
MLE rat 
monoclonal 
(6E11) 
ChIP 
WB 
2 mL 
1:500 
E. Kremmer (Helmholtz) 
MSL1 rabbit polyclonal WB 1:2000 E. Schulze 
MSL2 guinea pig polyclonal 
ChIP 
IF 
WB 
2 L 
1:1000 
1:2000 
C. Regnard (Pineda) 
MSL2 rabbit 
polyclonal 
(SA4868) 
IF 1:1000 T. Fauth (Eurogentec) 
MSL2 rabbit polyclonal IF 1:500 C. Regnard (Pineda) 
MSL2 rat 
monoclonal 
(1D6) 
WB 
IF 
1:500 
2 mL 
E. Kremmer (Helmholtz) 
MSL3 goat polyclonal WB 1:1000 M. Kuroda 
MSL3 rabbit polyclonal 
ChIP 
IF 
2 L 
1:100 
C. Regnard (Pineda) 
MSL3 rat 
monoclonal 
(1C9) 
IF 1:2 E. Kremmer (Helmholtz) 
MOF rabbit 
polyclonal 
(SA4897) 
ChIP 
WB 
2 L 
1: 2000 
M. Prestel (Eurogentec) 
SXL rabbit polyclonal 
IF 
WB 
1:500 
1:1000 
F. Gebauer 
TUB mouse polyclonal 
WB 
IF 
1:2000 
1:1000 
Abcam, Cat. No. ab44928 
Table 2: Secondary antibodies 
Antigen Conjugate Dilution Source 
Goat, guinea pig, mouse, rabbit, rat 
IgG 
HRP 1:20000 VWR 
Goat, guinea pig, mouse, rabbit, rat 
IgG 
IRDye 680RD 1:20000 LI-COR Biosciences 
Goat, guinea pig, mouse, rabbit, rat 
IgG 
IRDye 
800CW 
1:20000 LI-COR Biosciences 
Rabbit Ig AF555/AF647 1:400 Jackson Immunoresearch 
Rabbit Ig Cy3 1:250 Jackson Immunoresearch 
Rat Ig AF488 1:200 Jackson Immunoresearch 
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5.1.4 Consumables and instruments 
Amicon Ultra-4 Centrifugal filter (Merck Millipore); Bioanalyzer (Agilent); Branson 
Sonicator (Thomas Scientific); CASY Cell Counter (OMNI Life Science); 25, 75, and 170 cm2 
Cell Culture Flasks (Greiner); 12-mm round Coverslip (Paul Marienfeld); 24x60 mm Coverslip 
No. 1.5H (Carl Roth); Dialysis membranes (Spectrum Labs); Douncer (B. Braun); 1.5- and 2-
mL Eppendorf tubes; 15- and 50-mL Falcon tubes; Genesys20 (Thermo Fisher Scientific); 3-
well 14-mm Microscopy Slide (Thermo Fisher Scientific); Mr. Frosty Freezing Container 
(Thermo Fisher Scientific); Nanodrop (Thermo Fisher Scientific); 27G needle (B. Braun); 6-, 
12-well plate (Sarstedt); Qubit Fluorometer (Thermo Fisher Scientific); table-top Centrifuge 
(Eppendorf); Thermocycler (Eppendorf); Yamato LH-21 homogenizer (Triad Scientific) 
5.1.5 Oligonucleotides and in vitro transcripts 
Oligonucleotides are purchased from Sigma-Aldrich. In vitro transcribed RNAs are 
produced using the MEGAscript T7 Transcription Kit and purified with the RNeasy Kit. 
Table 3: Oligonucleotides for qPCR of roX1 and roX2 panels 
Panel Forward sequence (5’ to 3’) Reverse sequence (5’ to 3’) 
roX1 NP1 TAATCAGAGACCAGGGCACC TCGAAAAAGCCGAAGGGGAC 
NP2 CTCTGGCAAGATGTAGCGTC AAATGGCTTCTTTGGGATTG 
NP3 CTTCCCGGAGGAGTGTGGA CATCTCGTTGCTGTTGCGTTA 
NP4 TCTCTTTCGGGACTTGCAGT TGTAGACAAGGAGAGACGGC 
NP5 TCCGACCAGAAGTAGATCGTG CAATTGACGAGGTGCTGAACA 
NP6 TCGTTTTCCGAAATGGGAATCA AGGCTTTCAATACCGTTCCA 
NP7 TCTTCCCATTCTTGTGGATGCT CTTTGCAGCATATGAACAACGA 
roX2 NP1 GGCCTGGTCACACTAAGCTA ACCTAAACGCTCGACTTATGAT 
NP2 CGCAGTGCAACGTATACACA GGGAAAATTGAGCGGGTGTT 
NP3 TCTCCGAAGCAAAATCAAGCA TCGTACTCATCTCACTGTCCG 
NP4 ATGCAATACAATACAATACAAGACAAA TTCAGTTTGCATTGCGACTT 
NP5 GACGTGTAAAATGTTGCAAATTAAG TGACTGGTTAAGGCGCGTA 
NP6 AGCGAGATGACAATAGAGAGGC GCCATCTCTCTCTAAGCCAGC 
Table 4: Oligonucleotides for qPCR of embryo staging 
Name Forward sequence (5’ to 3’) Reverse sequence (5’ to 3’) Trend 
apc CTGAGGGCACTTGCTGATGT AAACGTCCTGGCTACGTCTG 
Up 
crag ACAAGTTGGGCAGCATTGTG CAACCCAGTGTTGTTGACCG 
cwo GCACTGAACCCGAGATAGCA CTGGACTCGGTGTGAACCTC 
socs16d CAACGGACCCTTTTTCAGCG CGAGGTCTCGCAGTTCGATT 
retn  CCTGAATCCACACAACATGG ACCGTGAGCGTAGTCATCCT 
Down Sr-CII GTGGTGGTGGTGCTATACCC CACAATTCGGGGACATTGCC 
zld  GTACTCACCGGAGTGGAAGC AAGTGTCTGGAGTGCGACAA 
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Table 5: Oligonucleotides for qPCR of ChIP efficiency 
Name Forward sequence (5’ to 3’) Reverse sequence (5’ to 3’) Target 
phlA  CTGTGCTATCTGCTCCCATGAT CGTTCAGCTCTAATCGCAAGC intron 
phlD  GGCCACTGCGAAAACTCG CGCCAACAGTTCGTACATCACG gene body 
phl hs  GAAGGGGACGGCTTTGGTT GGTCGGCAGGCAACCC HAS 
roX2 
SL3/4 
TCTCCGAAGCAAAATCAAGCA TCGTACTCATCTCACTGTCCG gene body 
roX2 hs AGCGAGATGACAATAGAGAGGC GCCATCTCTCTCTAAGCCAGC HAS 
set2  ATCTCGCGGT ACATCAACCA CACGCTGAAG AAACCAATGC gene body 
set2 hs GCGTACAGTAGCTGAGAGCTG GCGCCTTTACTGCATGTTAG HAS 
ubx f4  
TAGTCTTATCTGTATCTCGCTCT
TA 
CAGAACCAAAGTGCCGATAACT
C 
phantom 
peak 
ubx f12  GCCGTGGAGCAGTTCAAAGTA TCGTTGGTCGTGTCCTCTTAATT gene body 
runt  CACCAGATCTCAGCACGAACA CCGTGATACTCCTGCAGCATC 
ChIP 
efficiency 
Table 6: Oligonucleotides for dsRNA production to perform RNAi treatment of cells 
Name Forward sequence (5’ to 3’) Reverse sequence (5’ to 3’) 
Template 
(length) 
GFP  
TTAATACGACTCACTATAGGGTG
CTCAGGTAGTGGTTGTCG 
TTAATACGACTCACTATAGGGCCT
GAAGTTCATCTGCACCA 
Plasmid 
(479 nt) 
Jil-1 
TTAATACGACTCACTATACGGCC
GACATTTGGTTAGCTG 
TTAATACGACTCACTATAGGGCGT
GCTACCACA 
g/cDNA 
(667 nt) 
SXL I 
TTAATACGACTCACTATAGGGAG
AGATCACAGCCGCTGTCC 
TTAATACGACTCACTATAGGGAGA
TACCGAATTAAGAGCAAATAATAA 
gDNA 
(512 nt) 
SXL 
II 
TAATACGACTCACTATAGGGAGA
CCCTATTCAGAGCCATTGGA 
TAATACGACTCACTATAGGGAGAG
TTATGGTACGCGGCAGATT 
gDNA  
(412 nt) 
Table 7: Sequences of in vitro transcribed roX RNAs 
Name Sequence (5’ to 3’) 
roX1-5’ 
(518 nt) 
ATTACGTTCGGAGTGGAAAATGGAAATTAAGTGAAATATCCAGTGATCGATCGGTAA
TAGTAAATTGTTTGATACGTTTAGGCCAGTTGGTAAAGCAAATTAACAGCAGTTGTA
AGTAAATTTAATCAGAGACCAGGGCACCACACCCGAAAAGCGTGCAGATATTAGAA
GACATGGGCGTAGTTTCATATACGAGCTGTCCCCTTCGGCTTTTTCGACAAGTGGCAG
CCCTAATGGCCCTCGTTTTTTCGCCGACAAGCATTTAATGCGTAGTCACCGAAGAAA
AGTGTTAGTTACCAGGGCCTGCCCTTTTAAAATTAAATTTAAATTGAAAAAAAAAAT
CACCAAAAAATCGAAATCTCTGGCAAGATGTAGCGTCGAAAGAAAATTCATCAAAC
GGCATTGCCATCATCGTGCAGCAATCCCAAAGAAGCCATTTAGAATGCAGGCATCCA
GGCAAAAACCAGAAAACGTGCCTGTGGCAGCTGCACTTCGTGGCCTTGACGAGTCCG
GACAAT 
roX1-3’ 
(535 nt) 
ATCCGACCAGAAGTAGATCGTGTTCTGTGAACTAACCCCTTCAGTGTTCAGCACCTCG
TCAATTGTTCTTAATTGTTCCTTTTATTTTATGTTGTGTTATCTAATTAACTTCCGTTGT
ATTTTACCCAGTCCCCTTCCTTGACTTTCTAATAATTTTCCATGTTTTGACATATCCTT
TTTTGTCCCAGCCGAATAACCAACCATACTATTCCTATATAAGGTTCGTGTTTCGGAA
AACGCATTAAAAGGCGTAATTTTAAATCGTTTTCCGAAATGGGAATCACATTTAAAC
AATATTTTGAACTGCGTAAAACGAATAAATGGAACGGTATTGAAAGCCTATGCATTC
ATTACGGTTCAAGAAGTATAACTAAAAAAAAGGAATGAAAAAAAAAAAGAAAAGA
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AAAACACATTTACTAACAAATAAAAACTTGCTGATCAACGTTCTACGCAGTTCTTAA
AAAGATGTTGAAATGAACACAGCCAAAGCAAGTAAAAATGTGTGGAAACGTTATAC
GAATCTTCACCAAGTGCC 
roX2  
(552 nt) 
CCTGGTCACACTAAGCTAGGGCTACTTTTTATATCATAAGTCGAGCGTTTAGGTAGCT
CGGATGGCCATCGAAAGGGTAAATTGGTGTTACATATAGCTTTAGAGATCGTTTCGA
ATCACATTGATAATCGTTCGAAACGTTCTCCGAAGCAAAATCAAGCAAGAGTAACGA
TTTCCGCATAGTCGAAAATGTTTAAGTTGAATTGTCTTACGGACAGTGAGATGAGTA
CGACTATTTGGAAATCACAAACGAATTGTTTTCATGGTTGACGCGCTTGTCAAGCTAC
AAAACAAAATGAATGATATACAATATACAATATACAATATGCAATACAATACAATAC
AAGACAAAAAAATGTGTCTTGGAACGCAACATTGTACAAGTCGCAATGCAAACTGA
AGTCTTAAAAGACGTGTAAAATGTTGCAAATTAAGCAAATATATATGCATATATGGG
TAACGTTTTACGCGCCTTAACCAGTCAAAATACAAAATAAATTGGTAAATTTCATAT
AACTAGTGAAATGTTATACGAAACTTAACAATTGCCAA 
5.1.6 Cell lines 
Table 8: Cell lines used in the study 
Strain Origin Source 
Clone-8 (Cl.8+ CME W1) D. melanogaster wing disc, third instar larvae DGRC 
Kc D. melanogaster embryo, dorsal closure stage DGRC 
Schneider’s 2 (S2) D. melanogaster embryo, late embryonic stage DGRC 
5.1.7 Fly strains 
Fly strain used in most experiments is Oregon-R (wild type). A fly line expressing GFP 
under the SxlPe promoter is used for the analysis of protein expression in sex-sorted embryos 
(174). 
5.1.8 Bacterial strains 
Table 9: Bacterial strains used in the study  
Strain Genotype Source 
E. coli DH5a fhuA2 (argF-lacZ) U169 phoA glnV44 80 (lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
NEB, Cat. No. c2987 
E. coli BL21-
Gold (DE3)  
fhuA2 [lon] ompT gal [dcm] ∆hsdS Agilent, Cat. No. 230132 
5.1.9 Standard buffers and solutions 
Table 10: Standard buffers and solutions 
Solution Recipe 
Agarose gel TBE Buffer 
1% Agarose 
Ethidium bromide 
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Ampicillin stock solution 100 mg/mL Ampicillin (1000x) 
Buffer D 20 mM Hepes-KOH pH 7.9 
100 mM KCl 
3 mM MgCl2 
20% glycerol 
0.2 mM EDTA 
0.5 mM DTT 
Coomassie fixing solution 50% Ethanol 
10% Acetic Acid 
Coomassie staining solution 5% Ethanol 
7.5% Acetic Acid 
0.0025% Coomassie Blue (w/v) 
Dialysis buffer (MS2-MBP) 20 mM Hepes-KOH pH 7.9 
100 mM KCl 
20% Glycerol 
0.2 mM EDTA 
0.5 mM DTT 
Elution buffer for MS2-MBP Heparin column buffer 1 
10 mM Maltose 
Ethidium bromide stock solution 10 mg/mL Ethidium bromide (20000x) 
EX-50 buffer 10 mM Hepes-KOH pH 7.6 
10 mM KCl 
1.5 mM MgCl2 
10% Glycerol 
0.5 mM EGTA 
1 mM DTT 
0.2 mM PMSF 
Extraction buffer for NE 30 mM Hepes-NaOH pH 7.6 
450 mM NaCl 
10% Glycerol 
1 mM EDTA 
1 mM DTT 
PIC 
100x Fixing solution 500 mM Hepes pH 8.0 
1M NaCl 
10 mM EDTA 
5 mM EGTA 
HEMG buffer 25 mM Hepes-KOH pH 7.6 
100 mM KCl 
2 mM MgCl2 
20% Glycerol 
0.1 mM EDTA 
1 mM DTT 
0.2 mM PMSF 
1 mM NaMBS 
PIC 
Heparin column buffer 20 mM Tris-HCl pH 7.6 
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buffer 1: no salt 
buffer 2: 50 mM NaCl 
buffer 3: + 100 mM NaCl 
buffer 4: + 200 mM NaCl 
buffer 5: + 1 M NaCl 
Homogenization (NX-1) buffer 15 mM Hepes-KOH pH 7.6 
10 mM KCl 
2 mM MgCl2 
350 mM Sucrose 
0.1 mM EDTA 
0.5 mM EGTA 
1 mM DTT 
0.2 mM PMSF 
PIC 
5x Laemmli loading buffer 250 mM Tris pH 6.8 
50% Glycerol (v/v) 
10% SDS (w/v) 
0.05% Blue Bromophenol (w/v) 
0.5 M DTT 
LB agar plates LB medium 
2% Agar (w/v) 
LB medium 1% Pepton (w/v) 
0.5% Yeast extract (w/v) 
1% NaCl 
Lysis buffer for NE 15 mM Hepes-KOH pH 7.6 
60 mM KCl 
15 mM NaCl 
10% Sucrose 
0.5 mM EGTA 
0.5 mM DTT 
PIC 
Lysis buffer for WCE 50 mM Hepes-NaOH pH 7.6 
300 mM NaCl 
0.3% Tx-100 
PIC 
MNase enzyme solution 500 U resuspended in 850 L EX-50 
5% native PAGE gel 5% Bis-Acrylamide 
0.05% APS 
0.05% TEMED 
TBE buffer 
PBS(T) buffer 1.4 M NaCl 
27 mM KCl 
100 mM Na2HPO4 
18 mM KH2PO4 
(0.1% Tween-20) 
RIPA (Hepes) buffer 25 mM Hepes-NaOH pH 7.6 
150 mM NaCl 
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1% Triton-X-100 
0.1% SDS 
1 mM EDTA 
0.1% Na-deoxycholate 
1 mM PMSF 
PIC 
RIPA (Tris) buffer 10 mM TRIS pH 8.0 
140 mM NaCl 
1% Triton-X-100 
0.1% SDS 
1 mM EDTA 
0.1% Na-deoxycholate 
1 mM PMSF 
PIC 
SDS PAGE running buffer 25 mM Tris 
192 mM Glycine 
0.1% SDS 
Sonication buffer (MS2-MBP) Heparin column buffer 4 
PIC 
Sucrose cushion Lysis buffer for NE 
10% Sucrose 
Transfer buffer 25 mM Tris 
192 mM Glycine 
20% Methanol 
TRAX buffer I same as Homogenization (NX-1) buffer 
TRAX buffer II 15 mM Hepes-KOH, pH 7.6 
110 mM KCl 
2 mM MgCl2 
0.1 mM EDTA 
5% urea PAGE gel 8 M Urea 
5% Bis-Acrylamide 
0.05% APS 
0.05% TEMED 
TBE buffer 
Urea sample buffer 9 M Urea 
25 mM Tris pH 6.8 
1% SDS 
1 mM EDTA 
100 mM DTT 
TBE buffer 100 mM Tris base 
100 mM Boric acid 
2 mM EDTA 
TE buffer 10 mM Tris pH 8 
1 mM EDTA 
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5.2 Drosophila studies 
5.2.1 Drosophila husbandry 
Population of Oregon-R flies are maintained at 25C according to standard fly husbandry. 
5.2.2 Transcriptionally active embryo extract (TRAX) preparation 
Embryos of Oregon-R wild-type flies are collected every 12 hrs until a minimum of 100 g 
is reached. To stop them from developing further, embryos are kept at 4C for a maximum of 
72 hrs. Dechorionated embryos are then homogenized in 2 mL/g embryo of TRAX buffer I 
using the Yamato LH-21 homogenizer set to 1000 rpm in six passes. The homogenate is then 
filtered through a single layer of miracloth before further dilution to 5 mL/g embryo with 
TRAX buffer I. Nuclei are then pelleted by centrifugation at 10000 g, 4C, for 15 min and 
resuspended in 1 mL/g embryos of TRAX buffer II without disturbing the yellow egg yolk 
pellet. Supernatant is kept as cytoplasmic fraction. Nuclei suspension is fully resuspended by 
2 strokes of a B Dounce. 1/10 volume of room temperature 4 M (NH4)2SO4 pH 7.9 is added 
quickly and mixed by rapid inversion. Viscous solution of nuclei is rotated at 4C for 20 min 
and centrifuged at 150000 g, 4C for 2 hrs to pellet out insoluble fraction. Supernatant below 
the lipid layer is aspirated and precipitated out using 0.3 g/mL finely ground (NH4)2SO4 added 
steadily over a 5 min period, while stirring on ice. Proteins are pelleted by centrifugation at 
27000 g, 4C, for 20 min and resuspended in 0.2 mL/g embryo of HEMG-100. To remove 
excess salt, nuclear extract is dialysed against 2 L HEMG-100 for 4 hrs. Precipitate is spun out 
through centrifugation at 10000g, 4C, for 5 min and extract is stored in small flash-frozen 
aliquots at -80C. 
5.2.3 Embryo collection for IF and chromatin preparation 
Embryos are dechorionated using 25% commercial bleach and fixed in PBS/3.7% 
formaldehyde/heptane at 26C for 20 min, agitated. After formaldehyde removal, embryos are 
shaken in heptane/methanol (1:1) solution to aid devitellinization. Embryos are then rinsed in 
methanol and stored at -20°C. 
5.2.4 Immunofluorescence (IF) 
For IF staining, embryos are first rehydrated and washed in PBSTx-0.1% (PBS/0.1% 
Triton X-100). Blocking is done twice for 20 min each in PBSTx-0.1%/5% NDS. Both primary 
and secondary antibodies are diluted accordingly in block solution. Primary staining is done 
overnight at 4°C with agitation. Upon four washes of 15 min each in PBSTx-0.1%, embryos 
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are stained with secondary antibodies in dark at room temperature for 2 hrs with agitation. 
Embryos are then rinsed and washed four times in PBSTx-0.1% for 15 min each, the last one 
with added DAPI to stain DNA. Upon a final wash in PBS, embryos are mounted onto a 3-well 
glass slide in VECTASHIELD mounting medium, covered, and sealed with nail polish.  
5.2.5 Chromatin preparation from embryos 
For chromatin preparation, staged mixed-sex embryos are dechorionated in 25% 
commercial bleach and weighted. 1 g embryos are washed in 50 mL PBS/0.01% Triton X-100 
(PBSTx-0.01%) and resuspended in 10 mL 10x Fixing solution/3.7% formaldehyde. After 
addition of 30 mL n-heptane, embryos are rigorously shaken for 1 min and rotated at room 
temperature for 13.5 min. Following a spin at 2000 g for 1 min, crosslinking is halted by 
addition of 50 mL PBSTx-0.01%/125 mM Glycine. Washed embryos are flash-frozen and 
stored at -80°C until further use. Frozen embryos are resuspended in 10 mL Homogenization 
Buffer and dounced 20 times with a loose pestle and 20 times with a tight pestle before being 
spun down at 170 g for 10 min at 4°C. The nuclei pellet is resuspended in 4 mL RIPA (Hepes) 
Buffer. Fragmentation of chromatin is done either by MNase treatment or sonication shearing 
using the Covaris S220 instrument. To obtain similar digestion degree, stage 5-8 embryo are 
digested using 0.9 units MNase/g embryo and stage 13-15 embryo are digested using 2.9 units 
MNase/g embryo at 37°C for 30 min, shaking. Reaction is stopped by the addition of EDTA 
to a final concentration of 10 mM. Additional mechanical shearing is done by passing lysate 
through a 27G needle 15 times. Soluble chromatin is retrieved by centrifugation at 15000 g for 
15 min at 4°C. Chromatin fragment size distribution is evaluated on a Bioanalyzer.  
5.3 Cell biology methods  
5.3.1 Cell counting 
Cell concentration is determined using the CASY cell counter system as instructed. 50 L 
cell suspension is mixed with 10 mL CasyTon solution and measured with the set program, 
where viable cells with median diameter of 8 µm are called between 6-20 µm and debris 
counted as those below 3 µm. 
5.3.2 Maintenance of cell lines 
Kc and S2 cell lines are kept at 26C in Schneider’s Drosophila medium enriched with 
10% fetal calf serum (FCS) and 1% penicillin/streptomycin mix (P/S). Cl.8 cell line is 
maintained at 26C in Shields and Sang M3 medium supplied with 2.5% fly extract, 2% FCS, 
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5 g/mL insulin and 1% P/S. All components of cell culture are kept under sterile conditions 
and brought to room temperature before use. To maintain a 70% confluency, cell lines are 
diluted 1/10 every 72 hrs. 
5.3.3 Fly extract for Clone 8 cells 
Adult flies are collected in a 50-mL falcon tube and put in freezer for at least 1 hr. Frozen 
flies can also be stored for future use. 30 g frozen flies and 200 mL cold Shields and Sang M3 
medium are blended in a cooled blender until all flies appear lysed. Homogenate is spun at 
1500 g, 4C for 15 min. Supernatant is filtered through miracloth to remove larger debris and 
placed in a 60C water bath for 20 min to inactivate tyrosinase. Homogenate is spun again at 
1500 g, 4C for 90 min. Supernatant is filtered through a 0.22 m filter, aliquoted and flash-
frozen in liquid nitrogen. Fly extract is stored at -20C. 
5.3.4 Cryopreservation and thawing of cells 
Cells are seeded to a density of 1x106 cells/mL 3 days prior to freezing. Collected cells are 
spun at 500 g, room temperature for 5 min. Cell pellet is resuspended in freezing medium and 
aliquots of 10x106 cells/mL are frozen gradually first at -20C for 24 hrs then at -80C for 
another 24 hrs in a freezing container before transfer to liquid nitrogen for long-term storage. 
Kc and S2 cells are frozen in FCS supplemented with 10% DMSO, whereas Cl.8 cells are 
cryopreserved in Shields and Sang M3 medium enriched with 2.5% fly extract, 10% FCS, 5 
g/mL insulin and 10% DMSO. To thaw, frozen cells are quickly warmed up in a water bath 
and transferred to 5 mL culture medium in a 75 cm2 culture flask for at least 1 hr. Once cells 
attach, medium is changed to remove DMSO. Slow freezing and quick thawing preserve cells 
best. 
5.3.5 RNA interference in cells 
Genomic DNA or plasmid containing cDNA template is used to amplify ~500 bp PCR 
product containing a T7 promoter site and sequence of target of interest. Purification of product 
is done using the PCR Clean-up Kit as instructed and is thereafter used as template in an in 
vitro transcription reaction using the MEGAscript T7 kit. Generated RNA is treated with 
DNase and precipitated using lithium chloride. For the formation of dsRNA, sample is 
denatured by heating at 85C for 10 min and let cool to room temperature. 
To carry out RNA interference (RNAi) experiments, 1x106 cells in log growth phase are 
seeded in each well of a 6-well plate in 1 mL of serum-free medium. 10 g of dsRNA is added 
per well. Plate is shaken for 10 min and incubated at 26C for 50 min before 2 mL of fresh 
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medium is added. Cells are allowed to grow for an additional 4 to 14 days before analysis. To 
achieve better efficiency, fresh dsRNA can be supplied similarly between first treatment and 
analysis. 
5.3.6 Immunofluorescence of cells 
To start immunostaining, 0.5-0.8x106 cells are seeded onto coverslips treated with poly-
lysine and let attach for 1 hr at 26C. Carefully, cells are washed twice in PBS and fixed for 
7.5 min in PBS/2% PFA on ice. To permeabilize, cells are treated with PBS/0.25% Triton-X-
100/1% PFA for 7.5 min also on ice. Upon a PBS wash, cells are then blocked in PBS/3% BSA 
for 1 hr at 26C. Thereafter, cells are incubated in diluted primary and subsequently secondary 
antibody in the blocking solution for 1 hr each with a PBS wash step in between.  
5.3.7 Whole cell extract preparation 
Whole cell extract is prepared from 2x108 cells in log growth phase. Cells are spun down 
and washed in PBS at 500 g for 5 min. Cell pellet is resuspended in 2 mL lysis buffer for WCE 
and passed through a 27G syringe 10 times. Cell suspension is rotated at 4C for 10 min before 
a centrifugation at maximum speed for 10 min. Supernatant is collected and 100 L aliquots 
of WCE is stored at -80C. Concentration of extract is measured by Bradford. 
5.3.8 Nuclear extract preparation from cells 
Nuclear cell extract is prepared from 200x106 cells in log growth phase. Cells are spun 
down and washed in PBS at 500 g for 5 min. Cell pellet is resuspended in 3 packed cell volume 
(pcv) lysis buffer for NE and supplemented with 0.3% fresh NP-40. Cell suspension is rotated 
at 4C for 8 min and slowly pipetted onto a sucrose cushion. Centrifugation at 1500 g, 4C for 
15 min is done to separate nuclei found below the sucrose cushion from the cytoplasmic 
fraction remaining above the cushion. Wash nuclei once in 3x pcv lysis buffer for NE and 
resuspend in 750 L extraction buffer for NE. Extract concentration is measured by Bradford. 
5.3.9 Chromatin preparation from cells 
1/10 volume of 10x fixing solution and a final concentration of 1% PFA is added to cells 
growing in log growth phase. Fixing of cells is done for 8 min at 26C and stopped by the 
addition of 125 mM glycine. Cells are spun down and washed twice in PBS at 500 g for 10 
min. Nuclei isolation is thereafter done by resuspending cell pellet in PBS supplemented with 
0.5% Triton-X-100 and PIC at a concentration of 70x106 cells/mL and rotated at 4C for 15 
min. Nuclei are collected by centrifugation at 1500 g, 4C for 10 min and washed once in PBS. 
Materials and Methods 
 36 
To solubilize chromatin, nuclei is resuspended in RIPA (Tris) buffer at a concentration of 
7x107 cells/mL, treated with 0.75 L/mL MNase activated with 2 mM CaCl2 and incubated at 
37C for 35 min. To stop reaction, 10 mM EGTA is added and sample is incubated on ice for 
5 min. A sheering step using Covaris at 50W, 20% amplitude for 8 min follows to aid in 
releasing insoluble factors. Supernatant containing the soluble chromatin fraction is collected 
after centrifugation at max. speed, 4C for 20 min and stored in aliquots of 100 L at -80C. 
5.4 Molecular biology methods 
5.4.1 General molecular biology methods 
General molecular biology methods are done according to standard protocols. 
5.4.2 DNA purification methods for NGS 
Generally, DNA libraries are purified using AmpureXP beads for sequencing. In order to 
preserve small fragments that are otherwise selected against, DNA is precipitated after 
phenol/chloroform extraction by ethanol and sodium acetate (NaOAc). Briefly, equal volume 
of buffered phenol-chloroform-isoamyl alcohol (25:24:1) is added to sample. Upon a quick 
strong vortex, mixture is pipetted onto a MaXtract tube (Qiagen, Cat. No. 129046) and quickly 
spun as instructed. The aqueous phase remains on top, while the organic phase migrates below 
the gel. The aqueous phase is re-extracted once more with equal volume of chloroform in the 
same tube if volume allows. Supernatant is then transferred to a fresh tube containing glycogen 
at final concentration of 0.5 g/L as a carrier and 1/10 volume of 3 M NaOAc and 2.5x volume 
pure ethanol is added. Finally, DNA is precipitated by a minimum of 30 min incubation at -
20C and a 15 min centrifugation at maximum speed. DNA pellet is then washed thrice with 
cold 70% ethanol, air-dried and resuspended in TE buffer. 
5.4.3 In vitro polyadenylation for NGS 
RNA libraries for direct-RNA nanopore sequencing are prepared from 6 g TRAX RNA 
first rRNA-depleted using the rRNA depletion kit and thereafter polyadenylated in vitro with 
2.5 U Poly(A) Polymerase incubated for 10 min at 37C. RNA is purified using the Agencourt 
RNAclean XP as per manufacturer’s protocol. 
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5.5 Biochemistry methods 
5.5.1 MS2-MBP purification 
Bl21 cells are transformed with plasmid #1665 encoding for the MS2-MBP fusion protein 
and induced with 0.1 mM IPTG for expression upon reaching OD600 of 0.6-0.8. Cells are 
harvested after 2.5-hr incubation at 37C, at which OD600 is around 1.6. To force cell lysis, 
bacteria pellet is resuspended in sonication buffer and sonicated using Branson Sonicator with 
setting 80 sec 10 sec ON and 20 sec OFF at 20% amplitude. Amylose beads are incubated with 
the homogenate at 4C on a rotating wheel and collected by centrifugation at 1000 rpm, 4C 
for 2 min. To elute MS2-MBP protein, beads are loaded onto a BioRad column with elution 
buffer for MS2-MBP and 0.5 mL fractions are collected. A heparin column is equilibrated 
using buffer 1 before loading fractions containing most MS2-MBP as analyzed on a Coomasie 
gel. Washes are done using buffer 2, and MS2-MBP is eluted using buffer 3 into 1 mL fractions. 
Fractions are analyzed once more on a Coomasie gel, and those containing the best MS2-MBP 
protein are dialyzed against Buffer D for 2 hrs and concentrated using a microcon to desired 
concentration. Flash frozen aliquots are stored at -80C. Heparin column can be reused, if 
washed with buffer 4 and stored at 4C in buffer 5 (175). 
5.5.2 MS2-MBP affinity chromatography 
100 pmol of MS2-tagged RNA diluted in Buffer D is incubated at 65C for 10 min and let 
cool for 10 min at room temperature to allow denaturation and renaturation. Then, 5-fold molar 
excess of purified MS2-MBP fusion protein is added to bind RNA in a rotating incubation at 
4C for 20 min. To immobilize RNA-MS2/MS2-MBP, equilibrated amylose beads are added 
and rotated together at 4C for 1 hr. Meanwhile, 1 mg extract is incubated at 30C for 15 min 
to remove endogenous ATP. Once beads are washed twice with Buffer D, 1 mg extract, 1 mM 
ATP, 15 ug tRNA and RNAsin are added. RNP reconstitution is allowed to take place at 26C 
for 10 min, rotating. Upon completion, beads are washed twice with Buffer D at 4C for 10 
min each, rotating, to remove excess unbound factors. Elution of RNP complexes is done using 
10 mM maltose. RNA components are analyzed by PAGE bathed in ethidium bromide and 
protein components are analyzed by Western blot (WB). 
5.5.3 Chromatin immunoprecipitation (ChIP) 
1-2 µg soluble chromatin is used as input for each ChIP. Soluble chromatin diluted in RIPA 
buffer is first pre-cleared through incubation with protein A+G (1:1) beads, rotating at 4°C for 
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at least 2 hrs. RIPA buffer used in ChIP of cell chromatin is Tris based, whereas RIPA used 
for ChIP of embryo chromatin is HEPES based. Incubation of soluble chromatin with antibody 
of interest is done overnight and retrieved by incubation with 50% slurry mix of sepharose 
beads. For all ChIP using rabbit antibodies, slurry is made of protein A+G (1:1) beads, whereas 
rat antibodies are fished using only protein G beads. Reversal of crosslinking is done by an 
overnight incubation, shaking at 65°C. To rid of proteins and RNAs, sample is incubated with 
1 µg RNase for 30 min at 37°C and with 0.1% SDS/1 µg Proteinase K for 1.5 hrs at 55°C. 
DNA is then purified either using 1.8x volume AMPure XP beads or by phenol-chloroform as 
described above. ChIP efficiency is evaluated by qPCR and libraries for sequencing are made 
using the NEBNext Ultra II DNA Library Prep Kit for Illumina. 
5.5.4 Visualization of SDS PAGE gel 
Upon completion of SDS PAGE, gel is fixed in 50% ethanol/10% acetic acid for 5 min at 
room temperature, shaking. Fixed gel is stained with 5% ethanol/7.5% acetic acid/0.0025% 
Coomassie Brilliant Blue G-250 for another 30 min at room temperature, shaking. Destaining 
in water is thereafter done until protein bands are visible. To improve staining, gel can be heat 
up. Alternatively, gel is submerged in TBE/ethidium bromide solution to stain for nucleic acids. 
5.6 Data analysis  
5.6.1 Image analysis 
Images acquired on a Leica TCS SP5 confocal microscope are analyzed on software Fiji. 
5.6.2 Sequence analysis 
Sequence analysis is done using the software ApE (W. Davis) or SerialCloner (Serial 
Basics). 
5.6.3 Statistical analysis 
When possible, data are expressed as the mean ± standard error of mean. Statistical 
analysis is done using the Prism 8 (GraphPad Software) software. Gene expression analysis is 
calculated using the Pfaffl equation to determine relative difference in change of gene 
expression of a housekeeping gene and the gene of interest. 
5.6.4 Genome-wide analysis 
Alignment of MNase-based paired-end ChIP-seq reads to the reference genome (dmel 
release 6) are done using Bowtie2 (version 2.2.9). Single reads are filtered using samtools with 
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parameter -q 2, while paired-end reads are first subset into sub-nucleosomal (parameters: -I 10 
-X 130) or mono-nucleosomal (-I 130 -X 220) fragments and filtered using samtools with 
parameter -q 12. Reads are processed and normalized (to total number of reads and 
subsequently to input) using the Homer Software package (176). To call peaks on pooled 
replicates, Homer findPeaks tool is utilized with parameters -style histone -size 1000 -F 2.5 for 
MNase MOF and H4K16ac; -size 2000 -F 2 for MNase MSL2 mono-nucleosomal fragments 
or with -style factor -size 200 -F 6 for MSL2 sub-nucleosomal fragments. Composite plots are 
averaged replicates from input normalized bedgraph coverages centered at sites. MNase MOF, 
H4K16ac and MSL2 sub- or mono-nucleosomal coverages are centered to HAS in a 4 kb 
window and mean +/- 95% confidence intervals across HAS are visualized. Sub- or mono-
nucleosomal peak/region centered plots are generated in 4 kb or 10 kb windows, respectively. 
For correlation analysis at MSL2 peaks, ChIP enrichment is averaged in a 400 bp or 4 kb 
window for MSL2 sub- or mono-nucleosomal profiles, respectively, and Pearson correlation 
coefficient are calculated across samples and replicates. Meme (version 5.0.2) is used for de 
novo motif finding on MSL2 sub-nucleosomal peaks with parameters -nmotifs 1 -dna -revcomp 
-mod zoops -maxw 18. For genic analysis, MNase MOF and H4K16ac ChIP-seq and Input 
reads are counted over exons for each gene. Counts were normalized to TPM (similarly to 
RNA-seq). Finally, normalized counts were log2 transformed, Input is subtracted, and 
replicates were averaged. These genic ChIP enrichments were used for calculating Pearson´s 
correlation coefficients or for kmeans clustering (k = 3) to define high, moderate and low 
enrichment levels.  
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6 Results 
6.1 miRoX2 as a miRNA 
6.1.1 Hypothesis of a miRNA in development, miRoX2 
A series of pilot experiments from Sylvain Maenner led him to devise a hypothesis of 
a feedback loop that may act as a fail-safe mechanism in sex determination. The hypothesis 
states that roX1 and roX2 RNAs hybridize by base-pairing and the resulting hybrids are 
processed by the RNAi machinery into a miRNA, termed miRoX2, to induce the degradation 
of Sxl mRNA (Fig. 7). The Sxl mRNA is post-transcriptionally regulated to express a truncated, 
non-functional protein in male. Such a feedback mechanism would reinforce the negative 
regulation of Sxl in male that would otherwise negatively regulate the only male-specific 
protein in the DCC, MSL2. Interestingly, it would do so by involving another male-specific 
component of the DCC, roX RNAs. 
 
Figure 7. A hypothetical, non-canonical pathway of miRNA production may be involved in a 
feedback loop mechanism of dosage compensation. A) roX1-3’ and roX2 RNAs complement 
to form a hybrid. B) Upon hybridization, the RNAi machinery produces a miRNA, miRoX2, 
from hybridized roX. C) miRoX2 targets the 3’ UTR of Sxl mRNA to induce degradation. 
In these experiments, an MS2-MBP affinity chromatography was performed using 
various in vitro transcribed RNAs (Fig. 8A) to pull down proteins/complexes that interact with 
them upon addition of nuclear extracts (NE). The first set of results showed the hybridization 
of roX2 RNA with specifically the 3’ end of roX1 (roX1-3’) in a Northern blot analysis (Fig. 
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8B). Additionally, both roX1-3’ and roX2 RNAs seemed to interact with proteins of the RNAi 
pathway, such as DCR2 and AGO2 (Fig. 8C). Lastly, degradations of both RNAs were 
observed when mixed in the presence of NE of cells (Fig. 8D).  
 
Figure 8. Pilot experimental data from S. Maenner hinted towards a new hypothesis upon roX 
RNA hybridization. A) In vitro transcribed roX1-5', roX1-3’, and roX2 RNAs used in pull-
down experiments are denoted above schemes of roX genes. B) Northern blot suggested 
specific interaction of roX1-3’ and roX2 RNAs. C) roX1-3’ and roX2 RNAs interacted with 
DCR2 and AGO2. D) roX1-3’ and roX2 were degraded when incubated in NE of cells. Ticks 
represent roX boxes, boxes denote high-affinity sites on genes, and bulleted dashes indicate 
roX1 SL and roX2 SL7 and SL8. Introns are drawn in light shade, whereas exons in dark.  
Coincidentally, an expression profile from a genome-wide survey of sexually dimorphic 
Drosophila miRNAs became available (177). Indeed, a sequence of 19 nt that could have 
originated from roX2 RNA was only detected in 24-hr old male embryos, although not enough 
reads were reported for it to warrant annotation (177). This 19-nt sequence, 
“CAATATACAATATGCAATA”, was termed miRoX2, and through prediction algorithm 
searches on miRBase.org and microRNA.org, S. Maenner identified Sxl as one of its potential 
targets (Fig. 8). 
The data of S. Maenner was considered preliminary, but worth following up given the 
interesting implications in case of its confirmation. The roX genes would play two roles in 
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establishing and carrying out DC, namely by producing a lncRNA and a miRNA, with very 
different modes of actions. 
6.1.2 Revisiting miRoX2 hypothesis: do roX RNAs hybridize? 
Several things must be confirmed in recapitulating previous results, in order to conclude 
that an alternative feedback mechanism exists as hypothesized. First, the interaction of roX1-
3’ and roX2 RNAs; second, the binding of individual and hybrid RNAs with proteins of 
interest; and third, the degradation of the roX hybrid specifically. To probe for interaction 
between roX1-3’ and roX2 RNAs, hybridization experiments were carried out and analysed by 
electrophoresis. Included as control in the experiments were the antisense (AS) RNAs that 
should with no difficulties form hybrids with RNAs of interest. On a non-denaturing native 
PAGE, mixture of each RNA with its AS led to a different migration pattern, i.e. much faster, 
indicative of hybrid formation (Fig. 9A). Incubating roX1-3’ and roX2 RNAs together, 
however, did not (Fig. 9A). Each RNA migrated according to its own properties and the 
mixture of RNAs exhibited combined patterns where the two RNA bands were distinctly 
visible. As an unrelated positive control, dsRNA of Jil-1 3’ (667 bp) was run simultaneously 
and migrated faster than the combined roX1-3’ and roX2 RNAs (Fig. 9B). 
 
Figure 9. Attempts to recapitulate hybridization of roX1-3’ and roX2 RNAs failed. a) Mixing 
roX1-3’ and roX2 RNAs does not lead to a different migration pattern (lane 4) as seen in 
hybrids of either roX RNA with its AS RNA (lane 2, 6) on 4% native PAGE. As control, RNAs 
are run on 4% urea PAGE gel. b) As control, JIL-1-3’ dsRNA of similar size runs faster upon 
hybridization, while roX RNAs do not after incubation at various temperature for hybridization. 
Different parameters were tested to optimize the condition, including the temperature at 
which denaturation is done, the addition of a recombinant RNA helicase MLE at various 
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concentrations, and the salt molarity of the buffer (50 – 500 mM). Although positive controls 
worked, no hybrid formation could be observed between roX1-3’ and roX2 RNAs. 
As these methods are rather low in resolution and may not report on low affinities between 
the RNAs, reverse-transcription quantitative PCR (rt-qPCR) was performed to measure pulled-
down untagged RNA when a tagged RNA was used as bait. roX1-MS2 RNAs were first 
incubated with MS2-MBP protein and amylose beads. Thereafter, untagged roX2 RNA was 
added and let to hybridize. Upon several washes, RNAs bound to beads either through the MS2 
tag or via hybridization to bait RNA were purified and reverse transcribed. qPCR indicated 
poor hybridization of roX2 to roX1, regardless whether the 5’ or 3’ transcript was used, as 
pulled-down roX2 RNA was miniscule (Fig. 10). In comparison, preliminary observation 
showed quantitative hybridization of input RNAs (Fig. 8D). 
 
Figure 10. Miniscule untagged roX2 RNA was pulled down using MS2-tagged roX1-5’ and 
roX1-3’ RNAs as quantified by rt-qPCR. Values were normalized to untagged RNA sticking 
to beads and represented as percentage of input. 
6.1.3 miRoX2 degradation in NE of cells 
Naturally, a reason why hybridization may not take place is the absence of an RNA binding 
protein or remodeller that was present in the initial experiment from the addition of nuclear 
extract. To see whether hybridization and degradation can be seen in the presence of proteins, 
various extracts were added upon hybridization and binding of MS2-tagged RNAs to amylose 
beads. In addition to NE, cytoplasmic extracts (CE) and whole cell extracts (WCE) were also 
used. Binding of RNAs to MLE and a protein of the miRNA degradation pathway, DCR2, were 
visible on a Western blot (WB) as shown before. However, degradation of RNAs were not 
observed upon the addition of NE (Fig. 11A) or WCE (Fig. 11B) of cell lines L24, S2, and KC. 
The standard protocol dictates the denaturation and hybridization of both tagged and 
untagged RNAs first before binding to the MS2-MBP protein and immobilization onto amylose 
beads. Once incubated for 20 min, 1 mg extracts were added to allow for RNP reconstitution. 
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Another alteration introduced to improve the set-up was the order in which components were 
added to the reaction (reaction 2 vs. reaction 3 in Fig. 11). Assuming that the formation and 
subsequent degradation of hybrids might require the involvement of proteins in the extract, the 
untagged RNA was added simultaneously with extracts and incubated at room temperature to 
allow RNA processing to occur. Changing the order did not change the result and once again 
degradations of RNAs were not detected (Fig. 11). 
 
Figure 11. Incubation of roX RNAs in different nuclear (NE) or whole cell (WCE) extracts of 
various cell lines did not lead to degradation. Upon incubation in A) L24 NE and B) Kc or S2 
WCL, roX RNAs recruited MLE and DCR2 as seen by Western blotting; however, no 
degradation was observed. Addition of untagged RNA to the reaction was either done during 
the denaturation step (reaction 2) or RNA reconstitution (reaction 3). 
One last attempt to sort out parameters of the MS2-MBP affinity chromatography was to 
decrease the initial amount of RNAs while keeping all others the same. The standard protocol 
calls for an initial concentration of 333 nM individual RNA per reaction. In these experiments, 
a series of 1 in 5 dilution of input was done, with the lowest concentration being 2.7 nM of 
roX1-3’-MS2 and untagged roX2 RNAs each. Surprisingly, in all concentration tested, a 
decrease in RNA was observed upon the addition of 1 mg S2 NE (Fig. 12). Nevertheless, 
complete abolishment was seen when the least amount of RNAs were used, which represented 
2.7% of the initial set parameters, and was likely occurring due to a low degree of RNAse 
activity of the NE. The observations could not explain why such clear-cut degradation in the 
initial experiments were not reproducible. 
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Figure 12. Titration of input roX RNAs into S2 NE did not lead to degradation. roX1-3’-MS2 
was used to bait untagged roX2 RNA and analysis was done in an SDS PAGE. 
6.1.4 miRoX2-expressing stable cell lines 
For an in vivo exploration of the possibility that miRNA produced from roX2 could directly 
target Sxl mRNA, a female Kc cell line (K9) was created bearing an integrated construct of a 
pri-miRNA termed primiRoX2, where miRoX2 is packaged into the backbone of a ubiquitous 
miRNA, dme-miR-1 (Fig. 13A) (178). A canonical miRNA is generated from a pri-miRNA 
whereby a hairpin structure becomes the source of an RNA duplex carrying the seed sequence. 
If the hypothesis were true, miRoX2 miRNA would have to be produced by a noncanonical 
pathway, whereby the RNA duplex stems from the hybridization of two different lncRNAs. To 
simplify the system and possibly enhance expression and its consequence, a canonical scenario 
of miRoX2 production was designed in a female setting. Expression of pri-miRNA is induced 
by CuSO4 that activates the metallothionein promoter (Fig. 13B). Prior to experimentation, 
PCR was performed on isolated genomic DNA to ensure that the integrated construct had not 
been lost during maintenance, and indeed the construct was still fully integrated. 
To probe for protein expression, K9 cells were treated with CuSO4 for 10 days and protein 
extracts were analysed by Western blotting. SXL expression of K9 was compared to that of the 
parental Kc cell line, and a possible induction of MSL2 expression was analyzed against that 
of S2 cells. It can be concluded from a series of CuSO4-treatment experiments that SXL 
decrease and concomitant increase in MSL2 did not occur (Fig. 13C). One hypothesis for the 
lack of effect may be that upon treatment, expression of primiroX2 is not favourable to cell 
viability; therefore, those that do express are selected against and cells that do not express 
remain until the time of analysis. Shorter time-course experiments were performed to evaluate 
a more immediate effect, ranging from 24 to 96 hours; however, no observable difference in 
protein expression could be concluded. 
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Figure 13. An in vivo system with inducible primiRoX2 expression in K9 cells A) primiRoX2: 
miRoX2 (red) is packaged into the miR_1 backbone (green). B) MT_primiRoX2 construct in 
stable cell line K9 created by S. Maenner is inducible upon CuSO4 treatment. B) Proteins of 
interest in K9 cells were probed upon a 10-day induction and compared to levels in Kc and S2 
cells by WB. 
To test for transcript changes that might not have affected protein level, TaqMan Advanced 
miRNA Assay was performed alongside conventional rt-qPCR. rt-qPCR allows for detection 
of the primiRoX2 construct, whereas the qPCR-based TaqMan system enables highly sensitive 
quantification of mature miRoX2 through a looped primer design that specifically recognizes 
specific target. Control amplicons behaved expectedly, whereby GAPDH and dme-bantam 
(179) featured similar Cp values of ~25 and ~18 in all samples, respectively. primiroX2 
expression, however, was not detected upon induction of K9 cells for7 days, and consequently, 
mature miRoX2 was also not detected (Fig. 14). Cp values of either the pri-miRNA or the 
miRNA were well above 30, which is theoretically in the range of 2(35-30) or 32 molecules per 
sample, if Cp of 35 is used as a cut-off of expression.  
After multiple tries to recapitulate S. Maenner’s observations, quantitative degradation of 
roX RNAs could not be observed in presence of extract. First and foremost, no hybridization 
was detected. Addition of various extracts did not lead to roX degradation. Finally, placing 
miRoX2 sequence into a canonical miRNA backbone had no phenotype. If miRoX2 exist, we 
were unable to detect it reproducibly. 
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Figure 14. Expression of primiRoX2 and miRoX2 in K9 cells upon a 7-day CuSO4 treatment 
were negligible as assessed by conventional qPCR and TaqMan Advanced miRNA assay, 
respectively. 
6.2 Exploration into the biogenesis of functional roX RNAs 
6.2.1 Processing of roX1 and roX2 RNAs 
Redundancy of roX RNAs in DC has long been shown through various genetic 
experiments (116,118,121). The functional requirement of each roX RNAs is narrowed down 
to the roX boxes within SLs (93,125-127) and mutations (or lack thereof) of roX can be rescued 
by SLs from various related species (78,79,114). Interestingly, male cell lines that have been 
created from D. melanogaster preferentially express mainly one roX RNA, roX2. Reanalysis 
by T. Schauer of a recent transcriptomic study have also supported previous reports on heavily 
extensive post-transcriptional modification of roX RNA (117,129,131). Upon bulk RNA 
isolation from multiple stages of developing embryo, transcriptomic analysis of ribosomal 
RNA-depleted versus poly(A)-enriched samples pointed roX2 RNA processing (Fig. 15). 
Furthermore, a switch in promoter choice seemed to occur as development progresses (Fig. 
15). 
Considering the complexity of roX1 and roX2 isoforms, characterization of the dynamics 
and stoichiometry of isoform expression becomes imperative as different isoforms may have 
different functions. A method to quantitatively examine expression of RNA is by means of rt-
qPCR. A panel of primers was designed in such a way that combinations of reads could be 
used to deduce the isoforms. To do so, genomic sequence of roX1 and roX2 were first 
ascertained as qPCR is sensitive to single nucleotide differences in template. Sanger 
sequencing of gDNA retrieved from Oregon-R embryos and cell lines exposed annotated 
SNPs. The gDNA was thereafter used as standards in the quantitative determination of roX1 
and roX2 in subsequent experiments.  
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Figure 15. roX1 and roX2 RNAs in riboZero-treated and poly(A)-enriched transcriptomes 
during embryo development from Graveley et al., 2011, as reanalyzed by T. Schauer (131). 
roX1 scale: 0-19521 and 0-695, roX2 scale: 0-13331 and 0-58 in riboZero-treated and poly(A)-
enriched transcriptomes, respectively. 
6.2.2 Quantifying isoforms of roX RNAs in embryo extracts 
To quantify and characterize early expression of roX RNAs, two types of embryo extracts 
were used. The first is a nuclear, transcriptionally active embryo extract (TRAX) prepared from 
0-12 hrs old embryos (180). The second is a 0-90 min ael preblastoderm Drosophila embryo 
extract (DREX) that is rich in histones and factors of the chromatin assembly apparatus capable 
of reconstituting chromatin (181-183). Additional TRAX sample was kindly given by Andrea 
Lukacs and all DREX samples were gifts from Lisa Harpprecht. 
Prior to roX analysis, nuclear enrichment during TRAX preparation was ascertained by 
WB (Fig. 16). Nuclear proteins, such as MSLs and lamin, were indeed enriched in TRAX and 
depleted from the cytoplasmic fraction (CF) collected during the preparation, indicating that 
the fractionation and solubilization have worked. Accordingly, maternally deposited proteins 
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were detectable in DREX, i.e. MOF, MSL1, MSL3, MLE, but those that require zygotic 
machinery to be translated were exclusively seen in TRAX, i.e. MSL2 and SXL. 
  
Figure 16. Fractionation analysis of DREX, TRAX and its cytoplasmic fraction (CF). Various 
amounts of extracts were loaded and DCC proteins were visualized. Tubulin and lamin served 
as controls. Tubulin is present in all extracts; however, lamin is highly enriched in TRAX 
compared to CF. 
Next, the distribution of roX RNA in the TRAX, their corresponding CFs, and DREX were 
quantified using designed panel of primers (Fig. 17). Genomic DNA of embryos was used as 
standard to determine absolute amounts. First and foremost, it was surprising to detect both 
roX RNAs in DREX. Nonetheless, given the similar amounts of starting material, TRAX 
yielded much more roX RNAs, reflecting their steady-state transcription in late male embryos. 
A likely source of the measured roX RNAs in DREX may be contamination of older embryos 
during collection. A ratio analysis of roX1 RNA in TRAX versus DREX revealed that there 
might have been a promoter switch between the 0-90 min ael and 0-12 hrs ael extracts, as 
amplicon 1 indicated a greater enrichment over amplicon 3 (Fig. 17A). Furthermore, the long 
isoform of roX1, roX1-RE, was less abundant as amplicon 7 indicated the least gain of all. 
These observations are in line with previous findings (see above) of roX1 RNA undergoing a 
promoter switch and possibly alternative termination process through development (Fig. 17A). 
Concurrently, similar analysis of roX2 RNA indicated that alternative poly(A) sites might be 
used as development proceeds, as significant drop was seen between amplicons 4 and 5 with 
amplicon 6 (Fig. 17B). This trend is also in line with previous data (see above) of roX2 having 
alternative poly(A) sites that are functional at different stages of development (Fig. 17B). 
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Figure 17. Quantifying A) roX1 RNA and B) roX2 RNAs in 1 ng of total RNA of extracts. 
Ticks represent roX boxes, boxes denote high-affinity sites, and bulleted dashes indicate roX1 
SL and roX2 SL7 and SL8. Introns are drawn in light shade, whereas exons in dark. Numbered 
green and red dashes depict amplicons. TRAX and CF (n=3 each), DREX (n=2). 
Another interesting aspect disclosed by the TRAX to DREX ratio was enrichment of roX2 
over roX1 as development progresses. Taking into account amplicons specific for the major 
exons of roX1 and roX2 (amplicon 5 of roX1 and amplicon 3 of roX2), there was roughly 3 
roX1 for every roX2 RNA in DREX. On the other hand, 2 roX2 was measured for every roX1 
RNA in TRAX (Fig. 17). Remarkably, quite a significant amount of roX1 RNA were detected 
in the cytoplasm (Fig. 17). So far, such an export of roX1 RNA to the cytoplasm has not been 
described. As roX RNAs are also known to undergo intensive post-transcriptional processing, 
another interesting aspect of fractionation is whether there is a bias towards certain 
compartments if RNAs were polyadenylated. Similar TRAX vs. CF analysis was done upon a 
poly(A)-selection protocol (Fig. 18). Interestingly, up to 40% of total roX1 and 90% of 
polyadenylated roX1 was cytoplasmic, whereas a mere 5% of total roX2 and up to 60% of 
polyadenylated roX2 was measured in CF. Specifically, cytoplasmic RNAs tended to be the 
long isoforms of roX RNA, roX1-RE and roX2-RB. Differences in the distribution of roX 
suggested differences in processing as well biogenesis of these RNAs, which may be 
interesting functionally. To note, GAPDH amplicon used as control behaved as expected, 
whereby the majority of total and polyadenylated mRNAs are cytoplasmic (Fig. 18). 
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Figure 18. Percentage of total and polyadenylated roX RNAs in TRAX and the corresponding 
cytoplasmic fractions (CF) as quantified by qPCR. Two sets of primers were used for roX1 
(primer sets 2 and 5) and roX2 (primer sets 3 and 5) quantification. As control, amplicon of a 
GAPDH was used. Both total and polyadenylated GAPDH were cytoplasmic. 
6.2.3 Isoforms of roX RNAs in cell lines 
To study the interplay of roX expression as well as isoform distribution in previously used 
Cl.8 and S2 cells, quantification of roX RNA was done by rt-qPCR using the same panel of 
primers as before. To start, the bulk population of roX RNAs was determined in Cl.8 cells and 
compared to that of S2. There was roughly 2600 roX2 for every roX1 RNA in S2 cells. On the 
other hand, Cl.8 equally expressed them (Fig. 19A). Fractionation and subsequent 
compartmental analysis showed contrastingly that roX1 RNA of Cl.8 cells were mostly nuclear, 
having similarly small proportion of cytoplasmic fraction as that of roX2 (Fig. 19B). For both 
roX RNAs, however, the most 3’ amplicons showed a slight enrichment in CF compared to 
others, suggesting that at least some polyadenylated isoforms might shuttle in these cell lines 
as well. 
 
Figure 19. roX RNA expression in Cl.8 and S2 cells as quantified by rt-qPCR. A) Amounts of 
roX1 and roX2 RNA measured in bulk using amplicon 5 and amplicon 2, respectively. 
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6.2.4 Direct-RNA nanopore sequencing of total TRAX RNA 
Naturally, limitations are present with the use of qPCR to identify and quantify isoforms 
of RNA. To resort to a better and more accurate method, a pilot experiment of direct-RNA 
nanopore sequencing was performed on isolated RNA from TRAX. Ionic current passes 
through the nanopore as measured by potential difference across a membrane (184). As each 
nucleotide of an RNA transcript is pulled through the nanopore, a change in current occurs 
specific for the given nucleotide (184). Through machine learning of base-calling, the sequence 
of the entire RNA can be deduced. The advantage of direct-RNA nanopore sequencing over 
conventional qPCR is the elimination of biases during PCR amplification and reverse 
transcription. It also enables long-read sequencing of potentially full-length transcripts up to 
~2000 bases long (185). Furthermore, the possibility exists to identify any kind of post-
transcriptional RNA modifications as the read-out can be sensitive enough to these changes, 
such as m6A (186). Sequencing of native roX RNAs by direct-RNA nanopore sequencing 
without fragmentation would reveal isoform identities and modifications. 
A caveat of the method, however, is the need to pull RNA through a nanopore, which on 
its own has no specificity. It is equipped with a motor protein that feeds RNA into the nanopore 
and do so by recognizing poly(A) tails. In order to get an unbiased profile of all native RNA 
present in the TRAX, in vitro polyadenylation had to be done first. To assess efficiency, in 
vitro transcribed roX2 RNA was used as a reference. The single roX2 RNA population and the 
resolution of RNA analysis by Bioanalyzer enabled the determination of polyadenylation rate 
(Fig. 20). It is of importance that each RNA has a poly(A) tail, but not too long to avoid the 
mapping of mostly poly(A) tails. Thus, an optimization in the reaction setup was done to allow 
just enough polyadenylation. 
 
Figure 20. The progression of polyadenylation of nuclear RNA and in vitro transcribed roX2 
RNA were traced by Bioanalyzer analysis. 
Once the in vitro polyadenylation step had been optimized, libraries were prepared on 
isolated TRAX RNA that had first been depleted of ribosomal RNA using the rRNA Depletion 
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Kit (Fig. 21A-B). Performing depletion once or twice greatly reduced the rRNA peaks at 2 kB; 
however, double depletion also removed additional RNA larger than 500 bp (Fig. 21A). At the 
fear of losing larger roX RNA fragments, the single rRNA depleted sample was in vitro 
polyadenylated. A shift of RNA population towards larger size indicated that polyadenylation 
had worked (Fig. 21B). Population of sequenced reads mimicked the library profile, in which 
majority of fragments were between 0 and 500 bases (Fig. 21B-C). Unfortunately, larger reads 
seemed to be scarce. Furthermore, up to 50% reads still originated from ribosomal RNA despite 
the rRNA depletion step. Nonetheless, pilot sequencing appeared to work as mRNA of genes 
that are abundant in cells, such as ribosomal protein RpL32, were well detected and its long 
isoform sequenced (Fig. 21D). 
 
Figure 21. RNA library preparation for direct-RNA nanopore sequencing. A) Total RNA from 
TRAX was rRNA depleted once or twice. B) Once-depleted TRAX RNA was in vitro 
polyadenylated. C) Distribution of sequence lengths from Nanopore sequencing resembled the 
library profile in B). D) Reads aligning to the RpL32 locus. 
Only two sequences of roX2 and one of roX1 were obtained and mapped in this pilot 
experiment (Fig. 22). As expected, mapped reads stemmed from the most abundant parts of the 
roX RNAs. roX2 reads aligned to the major exon that is present in all isoforms. In case of roX1, 
the only aligned read represented part of roX1 sequence containing the roX box. Nanopore 
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sequencing proved to be a potential tool to study roX1 and roX2 heterogeneity; however, 
further optimization is needed.  
 
Figure 22. Direct-RNA nanopore sequencing reads for roX1 and roX2. 
6.3 Establishment of dosage compensation 
6.3.1 Transcriptomic measure as read-out of DC 
The aftermath of DCC acting on the X chromosome is an upregulation of its transcription. 
This presents an opportunity to use transcriptomics of embryos in various early stages as a 
read-out of when dosage compensation starts and proceeds. Single-embryo RNA sequencing 
of embryos performed by Tamas Schauer indeed highlighted peculiarities of the initial timing 
of roX RNA expression and dosage compensation during embryogenesis that are in line with 
previous reports (116,130). It was possible to determine the sex of each embryo from the sex-
specific gene expression in each dataset. Accordingly, a male balanced state can be construed 
as equal X expression relative to female embryos. Eight early stages were chosen for analysis 
based on phenotypical development as described by Bownes (4), the first of which was before 
ZGA (during formation of primordial germ cell) and therefore before sex determination. 
Phenotypical markers for latter stages included cellularization, early gastrulation, germ band 
elongation, stomodeum formation, germ band retraction, head involution, and dorsal closure. 
As expected upon comparison of median transcript levels, female embryos maintained an 
X to A ratio of ~1 as soon as it took control of its own transcription. Male embryos, however, 
required some time to reach the same ratio and were there ~10 hrs later, surprisingly long in 
time for DC progression (Fig. 23A). Nonetheless, this type of comparison has its caveats, as 
different pools of genes with different types of regulation are weighted against one another. 
For a less biased comparison, a fold change expression of female over male was computed for 
every gene and the average value was compared for every chromosome. Conceivably, 
autosomal genes were expressed similarly in all stages of interest, whereas X-chromosomal 
genes acquired a female bias upon ZGA, which was slowly neutralized with development (Fig. 
23B). Looking deeper into expression patterns, 20% of the least varied genes between stages 
were considered as constitutive, as supported by GO terms (metabolic processes, transcription, 
roX1 locus roX2 locus
5' 5' 3'3'
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translation) and acquired a balanced state rather quickly (Fig. 23C-D). Contrastingly, 20% of 
the most varied genes across stages were classified developmental as advocated by GO terms 
(anatomical and organ development) and maintained their female bias longer (Fig. 23C-D). To 
note, autosomal developmental and constitutive genes were equally expressed in male and 
female (not shown).  
 
Figure 23. Single-embryo RNA-seq as a measure of compensation. A) Ratio of X-
chromosomal over autosomal median transcript abundances (X/A) of preblastoderm (PB), 
female and male embryos in 7 developmental stages. Dotted horizontal line represents a ratio 
of 1, balanced transcript levels. B) Log2 Fold Change (log2FC) of RNA-seq between female 
(F) and male (M) embryos of expressed genes on X chromosome and autosomes in 7 
developmental stages. C) Heatmaps of log2 TPM (RNA-seq) values for X-chromosomal 
constitutive, 20% least variant, (left) and developmental, 20% most variant (right) genes. D) 
log2FC of RNA-seq of X- chromosomal genes which are constitutively or developmentally 
expressed. Data was generated by T. Schauer. 
According to Meller, roX1 RNA is transcribed in all embryos very early in development, 
whereas roX2 RNA is exclusively transcribed to a significant level in males beginning at stage 
9 when stomodeum appears (~6 hrs ael) (130). Consistently, roX RNA expression was similar 
in the single-embryo RNA sequencing dataset (Fig. 24A). Examining the rest of the DCC 
components, single-embryo transcriptomics confirmed the maternal contribution of msl-1, msl-
3, mof, and mle (Fig. 24A). As reviewed before, both Sxl and msl-2 are regulated at the post-
transcriptional level (50), explaining why their RNAs were detected in both sexes. 
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Nevertheless, Sxl transcript level was higher in females and msl-2 transcript level was higher 
in males (Fig. 24A) and their protein expressions were sex-specific (Fig. 24B).  
 
Figure 24. Expression of DCC components during timepoints of interest were determined in 
terms of A) transcript levels in single embryos and B) protein levels in sex-sorted embryos. 
GFP driven by the SxlPm promoter was used to mark female embryos. 
6.3.2 DCC by IF in developing embryos 
Previous immunofluorescence microscopy analyses described the emergence of MSL 
signal during the blastoderm stage of a male embryo, whereupon their colocalization on the X 
territory is only obvious by stage 8 (107,108). To see if with improved technology and 
sensitivity earlier observation of MSL staining was possible, embryos at various stages during 
development were stained with antibodies against various MSLs and H4K16ac. To set up the 
staining and imaging conditions, older embryos that were at least in stage 14, ~12 hrs ael, were 
used. Once optimized, male embryos were easily distinguishable from females as those having 
very clear confined signal of MSL2 and MSL3 in the X-territory of every nuclei (Fig. 25 panel 
4 and 5). Furthermore, clear colocalization of MSL3 and H4K16ac was identifiable (not 
shown), indicating that at this stage of development, DCC is present and active in its function 
to specifically acetylate H4K16 of the X chromosome.  
Delving a little earlier in development to embryos of stage 8, ~4 hrs ael, male embryos 
were also discernible through colocalization of MSL2 and MSL3 (Fig. 25 panel 2 and 3), as 
well as MSL3 and H4K16ac (not shown), at nuclei specifically undergoing mitosis. During 
gastrulation, certain localized cells of the embryo undergo division in order to support 
invagination and folding of tissue. Since nuclei compact during these divisions, concentrated 
amounts of MSL2, MSL3 and H4K16ac allow for signal detection on the X, which is absent in 
the rest of the nuclei. 
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Figure 25. DAPI MSL3 MSL2 IF staining on embryos at various stages of development. At 
stage 5, sex of embryos is not yet definable as obvious X-territories cannot yet be outlined. 
During gastrulation of male embryo [M] at stage 8, certain cells undergo mitosis, during which 
they condense and concentrate signals of MSL2 and MSL3. By stage 14, X territories are 
distinctly marked by MSL2 and MSL3 in all nuclei of a male embryo. Female embryos [F], 
whether in stage 8 or stage 14, do not attain MSL2 and MSL3 signal. 
Looking into embryos in the blastoderm stage proved to be a bigger challenge, whereby 
signal and background were not discernible (Fig. 25 panel 1). This was likely due to the low 
amount of protein of interest that is present at this stage of development and its distribution 
over a larger area. The first seven of 14 nuclear divisions occur within a window of ~8 min (5). 
To allow for such speed, nuclei at this stage are present in a decondensed state compared to 
dividing cells at later stages. The compaction of nuclei coincides with longer cycle times and 
correlates with increasing concentration of H1. By the end of nc 14 nuclei sizes decrease by 5- 
to 20-fold (187). Therefore, it is likely that lower amount of protein distributed over a larger 
area brings the signal below threshold of detection and therefore cannot be observed. 
Nevertheless, what appeared to be “shadows” of signal might indicate the start of X-territory 
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appearance, which was most obvious for MSL2 (Fig. 25 panel 1), the pioneering factor of the 
complex, and least obvious for H4K16ac, the product of an active complex. As 
immunofluorescence microscopy was not sensitive enough to resolve subtle changes in DC 
progression during the time window of interest, genome-wide profiling of DCC was performed. 
6.3.3 Genome-wide DCC distribution during embryonic development 
Since all components of the DCC appear to be present in these early stages of development 
where compensation is still incomplete, chromatin interaction of DCC members were probed 
by chromatin immunoprecipitation followed by sequencing (ChIP-seq) to determine whether 
this discrepancy was due to ineffectiveness of DCC and to understand mechanistically the 
process of compensation. MSL2 and MOF were chosen as proxy of DCC presence, and 
H4K16ac reveals DCC activity. Two windows of time during development were selected, the 
first encompassing 3 to 4 hrs ael, where most female bias was observed, and the second 
between 11 to 12 hrs ael, where constitutive genes were fully compensated. qPCR of 
developmental genes upon an H3K36me3 ChIP confirmed the embryo staging (Fig. 26A) and 
bioinformatics analyses were performed by T. Schauer. 
Past experience has proven ChIP to be quite sensitive to methods of solubilization and 
antibody sensitivity/cross-reactivity. In order to produce high-resolution chromatin interaction 
profiles, chromatin preparation was optimized, and antibody concentrations were titrated. 
Fragmentation through a combination of Micrococcal Nuclease (MNase) digestion and 
Branson sonication did not improve yield compared to MNase alone. An alternative shearing 
method by Covaris ultrasound increased DNA recovery but also destroyed the key protein, 
MSL2. Thus, the main method chosen was solubilization by MNase to preserve the integrity 
of factors. MNase, an endo-/exonuclease, digests nucleic acids until it hits an obstacle, e.g. a 
DNA-binding factor or a nucleosome. As a result, this solubilization method is also suitable to 
determine nucleosomal positioning and histone modification profiles. Nevertheless, it comes 
with its limitation: MNase largely acts based on the accessibility of nucleic acids; however, 
some sequence preference has been observed where it cleaves upstream of AT-rich region 
much more efficiently (188). On one hand, over-digestion will lead to digestion of histone-
associated DNA and will destroy MNase-sensitive nucleosomes; on the other hand, under-
digestion introduces noise during sequencing and will not truly reflect the nucleosomal 
landscape (189). To complicate matters, ChIP efficiency of various antibodies is affected by 
the degree of digestion. Hence, to lessen technicality differences, especially when using 
different input samples, a ratio of 4 to 1 of mono- to di-nucleosome was aimed for in every 
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MNase digest and a ChIP titration was done for every antibody. To evaluate the efficiency of 
pull-downs prior to sequencing, enrichment over X-chromosomal HAS for MSL2 and gene 
body enrichment of active X-linked genes for MOF and H4K16ac was determined by qPCR 
(Fig. 26A).  
An additional bioinformatics tool utilized was the ability to deduce lengths of DNA 
fragments upon paired-end sequencing of a ChIP experiment (190). Direct DNA binding of a 
factor allows crosslinking between DNA and the binding factor, marking a footprint 
appropriate to the size of the binding site. Protein-protein crosslinking events can also occur 
such as between nucleosomes and the DNA binder, protecting fragments of nucleosomal size. 
MSL2 is the only DCC subunit able to bind DNA (82-87). To specifically consider direct 
contacts of MSL2 with DNA, small fragments of sub-nucleosomal lengths, i.e. of 10 to 130 bp, 
were subset. On the other hand, longer fragments may indicate contacts of MSL2 with 
nucleosomes neighbouring the DNA binding site directly or indirectly via the DCC complex. 
To analyse such secondary occurrences, fragments of nucleosomal lengths, i.e. of 130 to 220 
bp, were referred to and termed chromatin interaction.  
In the early time window, MSL2 was present as seen by WB and was bound to DNA (Fig. 
25-26). Surprisingly, MOF and H4K16ac were also already abundantly present in the early 
time window and overlapped well with each other genome-wide (Fig. 26). 
Naturally, MSL2 binding at PionX sites and HAS were of interest and indeed, appreciable 
signal corresponding to direct DNA binding and to chromatin interactions up to ~2 kb away 
from these binding sites were found enriched (Fig. 27A). Early and late interaction profiles of 
MSL2 were very similar. It appears that within few hours after egg laying, MSL2 finds its 
target site on the X chromosome and “spreads” to neighbouring chromatin and the spreading 
was not more extensive at the late time.  
Similarly, MOF interaction was stably detected at and around PionX sites and HAS (Fig. 
27A). Unlike MSL2, MOF does not have the capacity to bind DNA on its own, hence, its 
presence at PionX sites and HAS could only be mediated by its assembly into DCC even at the 
early time window. Chromatin binding of MOF also overlapped well with that of MSL2 around 
these sites and intensified between early and late time windows to indicate ongoing assembly.  
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Figure 26. Genome-wide chromatin interaction profiles of MSL2, MOF and H4K16ac in early 
(orange) and late (purple) time windows. A) Stages were evaluated by qPCR upon an 
H3K36me3 ChIP. Amplicons chosen reflected up- or downregulated genes upon development, 
as described in Table. 4. Appropriately, apc, crag, cwo, and socs16d were upregulated, whereas 
Sr-CII, retn, and zld were downregulated. qPCR was also used to measure efficiency of MSL2, 
MOF, and H4K16ac ChIP, whereby MSL2 was better enriched at HAS, and MOF and 
H4K16ac at gene bodies (GB). Error bars represent SEM. B) Distribution profiles of MSL2, 
MOF and H4K16ac enrichment upon MNase-ChIP, normalized to input and total amount of 
reads. DNA and chromatin binding of MSL2 were differentiated through fragment length. 
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Called peaks/regions are represented as ticks/boxes above the tracks, respectively, and HAS 
below.  
To expand the analysis genome-wide, peaks of sub-nucleosomal and regions of 
nucleosomal fragments for each time window were called for MSL2 and MOF. To correlate 
them to the functional status of DCC, H4K16ac regions were also called. Upon comparison of 
MSL2 DNA and chromatin interaction, three different patterns were unveiled (Fig. 27B-C). 
First, 139 MSL2 peaks resided within regions of MSL2 association. They featured the 
published MRE motif and were mostly known HAS that often reside within introns (86,191). 
These sites seemed to be robust initial DNA binding of MSL2 that led to an X-enriched 
chromatin “spreading” and were termed “functional” with respect to establishing DC. Regions 
around these sites were also rich in MOF, indicating the assembly of DCC. Second were 202 
isolated DNA binding events that did not reside in regions of chromatin binding. Unlike the 
previous group, they lacked the GAGA-rich characteristic of MRE, and the majority were 
found on autosomal chromosomes. The lack of chromatin interaction suggests absent MSL3, 
leading to the conclusion that these binding events are rather “non-functional” in terms of DC. 
Indeed, almost no MOF were found at these sites. These newly identified sites might indicate 
transient interactions with accessible DNA detected through our optimized protocol. Last but 
not least, 199 chromatin binding regions were called that did not carry a direct DNA binding 
site, but nonetheless displayed binding of MSL2 and MOF. These regions without peaks did 
not have defined nucleosomal positioning and were not as intense in signal like the first group 
since they were plotted around the center of regions and not on the highest signal which would 
accumulate on a direct binding site. 
X-enriched regions of MSL2 were further subdivided into two groups depending on 
whether they were present early or late. Upon distance analysis to the closest MSL2 DNA 
binding site, a correlation of time and space was revealed. Late appearing regions were farther 
than the average distance away from the nearest MSL2 DNA binding site (Fig. 28A). 
Furthermore, intensities of MSL2 and MOF in the early regions did not change much but slight 
accumulation in the late appearing ones were evident (Fig. 28B). Nonetheless, it appears that 
the entire DCC complex is present where they should be already at the earlier time window 
and the small differences in MSL2 and MOF profiles are inadequate to explain the disparity of 
dosage compensation between the two windows of time.  
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Figure 27. DCC was present on the X chromosome at the early time window. A) MSL2 and 
MOF ChIP-seq reads were subset to sizes of 10-130 bp [DNA] or 130-220 bp [Chromatin] and 
plotted over known PionX sites and HAS. B) Peaks and regions of MSL2 were grouped based 
on overlap as represented in the Venn diagram. Average composite plot of [Chromatin] were 
generated for each group for MSL2 and MOF. C) Relative genome distribution of peaks and 
regions grouped in B and the most significant de novo motif analysis of peaks grouped in B. 
The delay of dosage compensation was clearly not due to the absence of MOF, but it was 
possible that MOF was not active as a HAT. Indeed, while the extent of MSL2 and MOF 
chromatin binding was unchanged, all averaging around 4 to 6 kb, H4K16ac regions extended 
from an average of 3 kb to 15 kb as development proceeded (Fig. 28C). Regions of acetylation 
extended far outside of MOF regions (Fig. 26B) specifically at X-chromosomal active gene 
bodies with time, while its writer, MOF, did so only to less degree (Fig. 28D). This suggests 
that MOF may reach out from its binding sites to acetylate remote chromatin through transient 
interactions. 
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Figure 28. Chromosome-wide H4K16ac requires time. A) Distance from centers of MSL2 
chromatin binding regions to nearest MSL2 DNA peak categorized whether they appeared 
early or late. Red lines indicate average distances. B) Average composite plot of MSL2 or MOF 
chromatin binding grouped by time of appearance. C) Distribution of MSL2, MOF and 
H4K16ac region sizes in the time windows. D) Average composite plots of MOF and H4K16ac 
ChIP-seq centered at Transcription Start Site (TSS) or Transcription Termination Site (TTS) 
in early or late embryos for X-chromosomal genes (total=1515).  
6.3.4 DC progression in time and space 
ChIP-seq of MSL2, MOF, and H4K16ac displayed the presence and activity of DCC, while 
single-embryo RNA-seq revealed the progression of DC. To correlate both events, X-
chromosomal genes were plotted according to their acetylation levels and grouped by k-means 
clustering. Three clusters emerged that provided insights into the workings of dosage 
compensation during early embryogenesis (Fig. 29A). To note, all genes on the X gained 
acetylation between the time windows, revealing the progression of dosage compensation. 
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Figure 29. Dosage compensation is progressive. A) Scatterplot comparing X-chromosomal 
genic H4K16ac ChIP-seq levels in stage 5-8 and 13-15 of mixed-sex embryos. Genes were 
grouped by k-means clustering (k=3). B) Log10 distance between the middle of a gene and its 
nearest functional MSL2 DNA peak in cluster 1 to 3. Red line is median distance to the nearest 
peak. C) log2FC of RNA-seq between female (F) and male (M) embryos at genes as clustered 
in A). D) Comparison of cluster 1 (top) or cluster 3 (bottom) genes as defined by H4K16ac 
ChIP-seq levels with constitutive and developmental genes as defined in Fig. 23C. 
The first cluster of genes were already highly acetylated at the early time window and were 
closer to MSL2 peaks compared to the median distance of X-chromosomal genes (Fig. 29A-
B). As illustrated in the single-embryo RNA seq dataset, these genes reached full compensation 
by stage 15 and contained most of previously defined constitutive genes (Fig. 29C-D top). 
Contrastingly, the third cluster of genes were lowly acetylated and lay far from MSL2 peaks 
compared to the median distance of X-chromosomal genes (Fig. 29A-B). Unsurprisingly, these 
genes were nowhere near full compensation by stage 15 and contained only 7 of 333 
constitutive genes (Fig. 29C-D bottom). Although only 172 genes were categorized into cluster 
3, as compared to 979 in cluster 1, roughly 25% of developmental genes (88-80 out of 333) 
were found in each cluster 1 and cluster 3, respectively (red overlap in Fig. 29D).  
6.3.5 Spreading of DCC 
Several conclusions can be made by correlating the spreading of DCC and progression of 
dosage compensation. First, genes are by and large acetylated in the early time window and 
reach full compensation 12 hours into development. Second, developmental genes reflect a 
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lesser dependence on dosage compensation, because they may only be relevant for the stage at 
which they are needed. Last, evolution selected placement of MSL2 binding sites near genes 
that require faster compensation, namely the constitutive, house-keeping genes. 
Long-range interaction of DCC with remote target genes is thought to be mediated by 
MSL3 contacting the transcription-associated H3K36me3 mark (70-72). In a final series of 
ChIP-seq experiments, MSL3 and H3K36me3 were included (Fig. 30). Profile of H4K16ac 
from the late time window in the establishment study was used for reference. 
 
Figure 30. DCC spreading originate from an initial interaction at HAS. A) Genome-wide 
profiles of MSL2, MSL3, MOF, and H3K36me in embryo chromatin from an overnight 
collection. H4K16ac profile is the same as from the late time window in Fig. 26. B) Distribution 
of DNA binding peaks (sub) of MSL2, chromatin binding regions (mono) of MSL2, MSL3, 
and MOF, and H3K36me3 and H4K16ac marks from ChIP-seq. 
Profiles of MSL2 and MOF from overnight embryos largely resembled that of the later 
time window obtained earlier, indicating that signal from an overnight collection was 
dominated by older embryos. As observed earlier, many MSL2 peaks were called on 
autosomes, but narrowing the list using the previous definition of functionality revealed their 
X-enrichment (Fig. 30B). Not surprisingly, H3K36me3 is found on all chromosomes. 
Nonetheless, MSL3 and MOF regions were clearly X-enriched, while autosomal distribution 
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of H4K16ac regions much smaller than those on X chromosome appeared quite significant 
(Fig. 30B). 
The genome-wide profiles of DCC members painted a picture of how a chromosome-wide 
regulation can be achieved once the X chromosome has been identified. DCC interaction with 
the X chromosome is initiated at X-enriched HAS by MSL2 through its direct DNA binding 
capability. From there on, the complex spreads onto gene bodies by means of MSL3 which 
recognizes H3K36me3 on active genes. MOF travels along and deposits H4K16ac. Although 
regions of MSL3 and MOF binding closely correlate with gene bodies marked by H3K36me3, 
H4K16ac regions extend far and beyond those gene bodies, suggesting that the H3K36me3 is 
not an absolute requirement for H4K16 HAT activity. 
6.3.6 Genome-wide DCC distribution in cell lines 
A fraction of MSL2 binding also occurs on autosomes, many of which are likely non-
functional. To narrow down the list of MSL2 peaks, a functional binding site had been defined 
as an MSL2 peak called within an MSL2 region. This definition differs from previous ones 
used under different experimental conditions. Straub et al. identify HAS as sites where MSL2 
and MLE bind, whereas Villa et al. consider HAS as MSL2 in vivo peaks that overlap within 
two genome-wide profiles both performed in S2 cells (86,91). Evidently, different sites of HAS 
are obtained, depending on the experimental set-ups. It is also conceivable that the softer mode 
of solubilization by MNase allowed the detection of more transient binding of MSL2. In 
addition to the conventional S2 cells, another interesting D. melanogaster cell line is the Clone 
8 (Cl.8) that originated from cells of the wing imaginal discs of a third instar larvae. It is one 
of the few male cell lines that expresses both roX RNAs (192). To compare the various HAS 
definitions, MNase-ChIP-seq of various DCC components were done in these cells and 
compared to the embryo profiles.  
HAS that were defined as MSL2 peaks within MSL2 regions in the establishment study 
were shared among overnight embryo, Cl.8 and S2 cells (Fig. 31A). As it has always been 
observed, however, ChIP-seq in embryos was more challenging than that in cells because of 
technicality differences. Embryos consist of mixtures of cell types with different chromatin 
accessibilities and gene expression. For example, five HAS were defined in the Tomosyn gene 
by Straub et al., one of which was also identified as a PionX site (86,91). In chromatin of cells, 
three of the five HAS were called with the highest signal belonging to the PionX site (Fig. 
31A). In chromatin of the overnight embryo collection, however, only one HAS that is also a 
PionX site was called (Fig. 31A). It is unlikely that the other HAS did not function, however, 
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crosslinking and subsequent immunoprecipitation might have been more efficient in cells, and 
therefore, better preserved weaker interactions. Interestingly, a gene that is highly relevant in 
neurons was marked by MSL2 and MSL3 in the Cl.8 cells but not S2, revealing that there may 
be some tissue-specific function of the DCC. The dunce (dnc) gene encodes a 
phosphodiesterase required for cAMP degradation. Its product is involved in neurological and 
behavioural plasticity including synaptic development and function. Conceivably, this gene is 
expressed in Cl.8 cells, but to a lesser extent in S2 cells (Fig. 31B). 
 
 
Figure 31. HAS in various tissues. MSL2 DNA and chromatin binding profile at the A) 
Tomosyn and B) dnc genes in Cl.8 and S2 cells as well as in chromatin of embryo from an 
overnight collection. HAS are as defined in Straub et al., 2013, PionX sites are as defined in 
Villa et al., 2016, and MSL2 functional sites are MSL2 peaks within MSL2 regions as defined 
in the establishment study. 
As MLE was successfully immunoprecipitated in cell lines upon solubilization by MNase, 
definition of HAS by Straub et al. as colocalization sites of MSL2 and MLE could also be 
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tested. MSL2, MSL3, and MLE distribution were highly similar in Cl.8 and S2 cells, also at 
the roX1 locus, which is only active in Cl.8 cells (Fig. 32A) (193,194). Genome-wide peak and 
region calling proved high overlap of MLE and MSL2 peaks that lay within regions of MSL2 
and MSL3 in Cl.8 cells (Fig. 32B), indicating that these were robust and DC-relevant events. 
Although more MSL2 peaks were called in S2 cells, only a minority overlapped with MLE 
peaks or were within a larger MSL2 domain (Fig. 32C). 
 
Figure 32. Cl.8 and S2 cells show similar DCC profiles. A) Genome-wide profiles of MSL2, 
MLE, and MSL3 from Cl.8 and S2 cells. The gene in the middle of the window is roX1. B) 
Overlap of MLE peaks, functional MSL2 peaks (MSL2 peak within an MSL2 region), and 
MSL3 regions called in Cl.8 cells. C) Distribution of peaks/regions called in ChIP-seq. 
In summary, two definitions of HAS were compared, i.e. HAS as “MSL2 peak overlapping 
with MLE peak” or as “MSL2 peak within MSL2 region”. Utilizing the Cl.8 or S2 datasets 
yielded similar results. Whereas “overlap of MSL2 and MLE peaks” yielded roughly 125 sites, 
430 MSL2 peaks were identified within MSL2 regions. This suggests that “MSL2 peak within 
MSL2 region” is a better experimental classification of HAS than MSL2 peak alone or even 
“MSL2 peak overlapping with MLE peak”. First, DNA binding that did not lead to spreading 
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were canceled out. Second, it did not rely on the mapping of MLE, which has been technically 
challenging due to its transient and RNA-dependent interaction. 
6.3.7 Cell lines as model for establishing dosage compensation 
To model dosage compensation establishment, female Kc cells were manipulated to induce 
SXL knockdown through RNAi. It has previously been shown that MSL2 is expressed upon 
removal of SXL in female cells (91,195), although this manipulation is not accompanied by 
massive changes in chromatin conformation (92). To determine if reducing SXL also alters roX 
RNA expression, roX RNAs were quantified under those conditions. Indeed, in addition to an 
increase in MSL2 protein expression (Fig. 33A-B), removing SXL induced both roX RNA 
expression (Fig. 33C-D). However, the extent of roX RNA expression in “sex-changed” Kc 
cells reached nowhere near that of S2 cells. In terms of roX1, RNAi-treated Kc attained half 
the expression, whereas roX2 was only expressed at roughly an eighth of that in S2 (Fig. 33C-
D).  
Induced MSL2 level in Kc was comparable to S2 (Fig. 33A). However, it was still 
insufficient to induce a chromosome-wide targeting of MSL2 to the X, whereby only the PionX 
sites acquired strong MSL2 binding after 3 days (91). As such miniscule amounts of roX 
transcription were measured in “sex-changed” Kc cells, roX RNA may just be the limiting 
factor. Highlighting the importance of roX RNA in the establishment of DC, understanding its 
biogenesis into a functional DCC RNP complex is of interest. 
  
Figure 33. Sxl RNAi of Kc cells. A) MSL2 expression was greatly induced upon SXL 
repression in Kc cells as analyzed by WB. B-D) qPCR analysis confirmed decrease in Sxl 
mRNA and increase in both roX RNAs. roX2 was more induced than roX1; however, the level 
reached in “sex-changed” Kc cells did not resemble S2 levels. 
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7 Discussion 
7.1 miRoX2 
The hypothesis by Sylvain Maenner that suggests roX1 and roX2 RNAs hybridize and by 
means of a non-canonical pathway produce a miRNA to negatively regulate Sxl could not be 
proven as his observations that would suggest so were difficult to reproduce. This raises the 
question whether such hybridization of two lncRNAs is possible and whether miRoX2 exist.  
7.1.1 lncRNA hybridization 
Efforts to hybridize roX RNAs have been done in various conditions with RNAs in the 
absence or presence of extracts. As all experimental attempts have failed, in silico predictions 
of RNA hybrids between roX1 and roX2 up to 100 nt upstream and downstream of potential 
miRoX2 interaction was done using the Unified Nucleic Acid Folding and hybridization 
package (UNAFOLD) tool. To note, any modelling of the roX RNA alone using similar 
prediction tools did not fit published experimental data on the secondary structures of roX 
RNAs (78,79), indicating that these predictions are of limited value. Sequences were fed into 
the algorithm, first starting with the region of interest containing miRoX2 and the corresponding 
sequence on roX1, followed by incremental addition of 10 nt to each end. Modeling did not 
reveal any potential hybridization between roX1 and roX2. With every addition, hypothetical 
secondary structure changed drastically and regions on corresponding roX RNAs thought to be 
the source of miRoX2 did not necessarily hybridize in every simulation. If hybridization were 
to occur under physiological conditions, it would very likely involve an RNA helicase that can 
promote annealing of ssRNAs, such as MLE (76,196). 
Interestingly, establishment of the mammalian system of dosage compensation through X 
inactivation also requires the working of two X-linked lncRNAs, X Inactive Specific Transcript 
(XIST) and its antisense TSIX (XIST in reverse), which is transcribed in the opposite direction. 
Contrastingly, while XIST silences the X chromosome from which it is transcribed by inducing 
chromosome-wide histone methylation through recruitment of the Polycomb repression 
complexes, TSIX acts to antagonize it on the active X chromosome by promoting XIST 
promoter methylation, indicative of silencing (197). Additionally, it is thought that TSIX 
transcription across the XIST promoter inhibits XIST expression, and as it is complementary to 
the XIST RNA, TSIX can repress XIST through antisense binding as a failsafe mechanism to 
prevent ectopic silencing (197). Therefore, it is not uncommon to find biological role in the 
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hybridization of two lncRNAs, and specifically in serving as “sponges” for miRNAs. 
Nevertheless, XIST and TSIX may work this way because they are expressed monoallelically 
on different chromosomes and have opposing effects in the final outcome of silencing. 
Furthermore, XIST and TSIX are perfectly complementary to each other, whereas roX1 and 
roX2 show only limited complementarity. What would be the biological context to which roX1 
and roX2 RNAs, each conducive towards upregulation of the X on their own, require the 
presence of the other to carry out its role or to antagonize each other? And under which 
circumstances would such interaction be favourable? 
7.1.2 Does miRoX2 exist?  
In the original study by Fagegaltier et al., less than 50 short sequences corresponding to 
miRoX2 were detected specifically in males upon miRNA sequencing (177). In comparison, a 
well-known and annotated miRNA, dme-miR-1, was found more than 450,000 times, pointing 
towards the possibility that miRoX2 sequences may be degradation products. To explore 
potential targets of miRoX2, searches for miRNA family with similarity in seed sequence was 
done in the miRBase database (release 22.1, October 2018). The first family identified with the 
least mismatch was dme-miR-2489 with an E-value of 17 that is equivalent to a p-value of 
0.9999999586, indicating that a likeliness is quite improbable. Using the latest release of 
TargetScanFly (release 7.2, October 2018), Sxl was indeed identified as the second best hit of 
potential dme-miR-2489 targets. Nonetheless, the low number of sequences found in the 
original small RNA dataset in flies (177) and the improbable likeness of miRoX2 to dme-miR-
2489 rather suggest that the probability of such an event is very small. 
Target prediction tools infer minimalistic condition, in which the sequence of a candidate 
miRNA is matched base-per-base with sequence of potential mRNA targets. When calculating 
minimal free energy values and probability of certain miRNA-mRNA interaction, the 
algorithms assume a linear unfolded free mRNA that float freely with an unlimited supply of 
miRNA. In reality, mRNAs are bound by RNA-binding proteins to ensure stability and avoid 
false interactions (133). Thus, successful interaction of miRNA with mRNA must in all cases 
win over any other competing transcripts and interaction partners and unless robust detection 
of a miRNA is seen, its source annotated and its target identified, it is difficult to ascertain the 
presence of one.  
Considering the high variability of results, it is concluded that the system is very complex 
and may only happen under very specific condition. The hypothesis that roX RNAs can together 
produce a miRNA that leads to Sxl mRNA degradation would present a feedback loop that 
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reinforces the establishment of sex determination and dosage compensation by the boosting of 
SXL repression and MSL2 expression in males. This may explain why a stably sex-determined 
system such as a male cell line may not have much need for it and why tissue culture cells may 
not be a good model to study it. However, as both processes are already well defined without 
the involvement of miRoX2, why should such a system require miRoX2?  
Transcriptomic study of single embryos during development illustrates the time window 
in which roX1 and roX2 RNAs may potentially meet. roX2 is expressed later than roX1. Based 
on the compensation measurement and binding event of DCC to the X chromosome, by the 
time roX2 is expressed, the male phenotype has already been established and thereby a 
potential function of miRoX2 may simply be to strengthen the male line of development. 
Alternatively, hybridization of roX1 and roX2 RNAs could function in females as means of 
“sponging” out spurious, albeit low level, expression of roX2, which may otherwise negatively 
influence Sxl expression. In this case, roX1 RNA negatively regulates by sequestering miRoX2, 
thus limiting their availability in the cell, and by extension, positively regulates Sxl. However, 
initial RNA concentrations used in the pilot experiments of miRoX2 were much too high and 
so the question arises if interaction between roX1 and roX2 was observed because the system 
was pushed to increase the probability of roX RNAs finding each other and the original miRoX2 
sequence is simply a degradation product of roX2. 
7.1.3 Unique pathway of miRNA production  
As has been introduced, conventional miRNA production involves a pri-miRNA transcript 
that contains a stem-loop of hybridized sense and anti-sense sequences. If the hypothesis that 
the 3’ end of roX1 is able to hybridize with roX2 to form a pri-miRNA construct were true, it 
would present a unique observation of a non-canonical processing of a miRNA. In this case, 
the sense and anti-sense sequences originate from two different sources and their processing 
into a functional miRNA would rely on various parameters including the transcription rate, 
stability, and secondary structure of each individual RNAs. 
The common practice of identifying a miRNA is by a combination of computational, 
biochemistry, and genetic methods (198). Unfortunately, computational predictions yielded no 
convincing results, whether in finding a similar family of miRNA or identifying a potential 
target. All biochemical results that were initially observed were difficult to reproduce, although 
many types of experiments and methods were exhausted. As a final attempt, a female cell line 
was generated to express miRoX2 in the context of a canonical RNAi pathway. To increase the 
production efficiency and enhance subsequent effect in an in vivo setting, an inducible system 
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to express primiRoX2 was used, whereby miRoX2 is packaged into a backbone of a well-known 
pri-miRNA that undergoes conventional miRNA processing (178). Unfortunately, neither the 
synthesis of miRoX2 nor an effect on Sxl repression was obvious when the construct was 
induced for various timepoints. Although stimulation of primiroX2 transcription could be 
improved, the question remains if miRoX2 really exists. 
The majority of miRNA arise from miRNA gene families, but it has been widely observed 
that their origins can be the 3’ UTR of their own targets as well as pseudogenes that encode 
lncRNAs (133). These pre-miRNAs undergo nuclear processing by Drosha, followed by 
cytoplasmic processing by DCR to produce the final miRNA. Several non-canonical pathways 
of miRNA production have been reported in different kinds of species that are independent of 
Drosha (199). Mirtrons, which are pre-miRNA sequences embedded within introns of genes, 
are exported upon processing by spliceosomes for further cutting by DCR (199). Other sources 
of miRNA include small-nucleolar RNAs, short hairpin RNAs, as well as tRNAs, and are 
Drosha-independent but prove to be substrates for DCR cleavage (199). None of the reported 
examples, however, presented a case in which duplex of two lncRNAs produce a miRNA, 
except for one study of XIST and TSIX that has not been reproduced (200,201). Ogawa et al. 
reported that upon formation of a XIST:TSIX duplex on the active X chromosome in vivo, it is 
processed into small RNAs they termed XiRNA in a DCR-dependent manner and ablation of 
DCR leads to ineffective X silencing (200). Kenellopoulou et al., however, observed that 
establishing X inactivation does not require DCR, but it may influence the stability of XIST 
and its ability to coat the X (201). Although the experiments performed were quite different in 
design and the debate is still open whether XiRNA truly exist, and if so, to which extent they 
are required, i.e. establishment or maintenance of silencing (202), it is interesting to note that 
RNAi machinery and dosage compensation may intersect in different species and production 
of such small RNAs as feedback loops has been hypothesized before. 
7.2 roX RNAs 
Expression of roX RNA changes during development as has been observed since its first 
reports. roX1 is present in male and female since onset of ZGA, whereas roX2 is male-specific 
and more abundantly expressed roughly 2 hrs later (116,121). The switch in roX1 and roX2 
stoichiometry in parallel with the progression of compensation proposes differential roles or 
efficiencies of their part in DCC. 
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7.2.1 Differential functionality of roX1 vs. roX2? 
Many stable cell lines of the male phenotype from D. melanogaster express roX2 much 
higher than roX1, which may be an adaptation to simplify DCC in a more homogenous system 
(193,194). For this reason, the Cl.8 cells that persist to express both roX RNAs pose an 
interesting biological setting to compare and contrast roX1 and roX2 RNAs. 
Nuclear and cytoplasmic analyses of roX RNAs point toward contrasting distribution that 
may indicate distinct pathways of biogenesis. Although contamination may have introduced an 
artifact during the procedure, the presence of roX RNA in the cytoplasm may be biologically 
relevant. Poly(A)-enriched RNA profiles also suggest that roX RNAs undergo post-
transcriptional processing that may involve its shuttling in and out of the nucleus. lncRNA are 
not largely known to shuttle between compartments unlike other non-coding RNAs such as 
miRNAs and tRNAs; however, a recent study in hepatocellular carcinoma cells proposes the 
shuttling of a lncRNA, MALAT1, as a crosstalk between the nucleus and mitochondria (203). 
And so, it is attractive to reason that roX RNAs, due to its polyadenylation, moves between 
compartments. A hypothetical function of such shuttling of roX1 may be to assist the formation 
of DCC in the early stage of development, during which roX1 is more prevalent. Although 
mRNAs of MSL1, MSL3, MOF, and MLE proteins are deposited into the egg, their translation 
to reach the homeostatic threshold may still require time. The shuttling of roX1 RNA to the 
cytoplasm can therefore act as an assembly platform and facilitate faster formation of DCC, 
which would require the need to import sub- or full complexes of DC back into the nucleus. 
Contradicting reports on the associations of nuclear pore complex with MSL3 and MOF have 
been published (204,205), so it remains to be elucidated whether shuttling of roX RNAs is true 
and has a functional role in DC. Nevertheless, more and more evidence support the idea that 
roX1 and roX2 RNAs have separate roles and would explain their co-evolution through various 
Drosophilid species despite a functional redundancy in DC (114,206).  
7.2.2 Quantification methods 
Initial experiments to quantify roX RNAs and characterize their isoform expression were 
done through rt-qPCR. Although the method was well enough to indicate relative amounts of 
transcripts, it had drawbacks that led to absolute quantitative inaccuracy. First and foremost, a 
crucial part of the method is reverse transcription, which on its own introduces bias towards 
the 5’ end of targets. Second, quantitation against a standard requires prior knowledge of the 
underlying sequence as the method is sensitive to single base mismatches between primer and 
target sequence due to SNPs present in both roX genes. Third, quantification of various regions 
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of an RNA species relies on the efficiency of various primer pairs and may not be analogous 
across the panel. The comparison of amplicons 3 and 4 of roX2, both of which should have 
detected all isoforms, showed variation by as much a 2-fold factor in the analysis of TRAX 
RNAs (Fig. 17). Although many improvements have been introduced to qPCR to allow for 
more accurate absolute quantification (207), more recent genome-wide methods of RNA 
sequencing provide an enticing platform to do so (208,209). 
One such is direct-RNA sequencing using the Nanopore technologies. A pilot experiment 
has shown potential in characterizing roX isoform profiles. Interestingly, regions of both roX 
RNAs that are of great interest and relevant to DC were detected albeit at a very low level. In 
this experiment, the bait used to attract RNA to the nanopore was the poly(A) tail. In principle, 
custom adapters can be designed to target specific RNAs for sequencing (Oxford Nanopore 
Technologies), but such studies have not been published so far. Nevertheless, targeted RNA 
sequencing can perform simultaneously as an enrichment tool and might help in profiling 
isoforms of roX RNAs. A foreseeable caveat may be that 3’ ends of roX isoforms differ, but 
comparison of expected major isoforms of roX1 and roX2 could already shed more light into 
the biogenesis of roX RNAs. 
7.3 Dosage compensation  
Dosage compensation presents an interesting biological phenomenon in which the 
assembly and targeting of a complex lead to a chromosome-wide regulation. Additionally, this 
complex requires the interplay of not just various proteins with enzymatic capabilities but also 
lncRNA to refine its placement and function within the nucleus. Although their importance is 
repeatedly reiterated, how they influence the workings of gene regulation mechanistically 
remains to be resolved.  
7.3.1 Gradual acquirement of dosage compensation 
Considering all the enormous changes happening during the early hours of embryogenesis, 
it is interesting to see that the establishment of dosage compensation occurs in a very 
progressive manner over a long period of time, up until at least 12 hrs ael (210). As the need to 
compensate arises, evolution must have retained an order of events that is most beneficial for 
the organism and as the mechanism to balance dose advances gradually, traces of evidence at 
how the solution came about are left behind. 
The genome-wide analysis of MSL proteins reinforced the scheme that is used by DCC to 
perform its function in regulating X-chromosomal transcription. MSL2, as the pioneering 
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factor, identifies sites on the X chromosome that have accumulated in such a way that genes 
relying on DCC are closer to them than those that are rather less dependent. Upon recruitment 
of MSL2 to these high affinity sites, the rest of the complex is brought along via MSL1, the 
scaffold protein. MSL3 then identifies active gene bodies around these sites to allow specific 
H4K16 acetylation by MOF. roX RNA and its remodeller, MLE, refine the targeting of the 
entire complex and facilitate its spreading to blanket the entire X chromosome.  
MSL2 binding as well as MOF recruitment to HAS are clearly evident 3 to 4 hours ael 
(210). These profiles do not widely change by 11 to 12 hours ael, indicating that most of the 
initial events in identifying binding sites on the X chromosome and active gene bodies have 
ensued. Nevertheless, gain in the acetylation level of H4K16 of X active genes indisputably 
occurs (210). The increase in H4K16ac level as well as its spatial distribution are very likely 
facilitated by the refinement of the chromosomal landscape during early embryogenesis 
(28,29). However, this does not rule out the possibility that a mechanistic switch occurs in the 
progression of time that increases the activity and/or efficiency of the complex. Such a switch 
could be the presence of roX2, as its expression occurs coincidentally with the gradual reversal 
of the female-biased X expression. 
7.3.2 Spreading mechanism of DCC 
HAS serve as nucleation sites, which allow DCC to concentrate on the X chromosome and 
spread either through an active mechanism or by diffusion (82,84,85,87,90,97,195,211,212). 
roX RNAs have been shown to promote efficient spreading of the DCC along the X 
chromosome (93,94,191). It may partly be due to the X-linkage of the roX genes, whereby 
autosomal integration of either roX genes has been shown to cause in cis spreading 
(82,116,121,122). Alternatively, active transcription through CES found in the main exon of 
roX1 and at the 3’ end of roX2 may be relevant to the establishment of DC through some 
unknown mechanism.  
Changes in roX1 and roX2 concentrations in parallel with the progression of compensation 
also propose differential roles or efficiencies. Given that MSL1-mediated dimerization has 
been implicated in targeting and spreading of DCC (64), a hetero-tetramer core complex of 
MSL1-MSL2 subunits would recruit two units of other DCC members, including roX1 and/or 
roX2 RNAs. Interestingly, Ilik et al. was unable to detect roX1 and roX2 RNAs within the same 
complex in a ChIRP study (78). Therefore, it is tempting to characterize distinctions of a DCC 
containing roX1 RNA and a DCC containing roX2 RNA. With the obvious difference in 
expression timing, it is appealing to posit that roX1-DCC is the major form in early 
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development and is sufficient for the recruitment and binding of DCC to the X chromosome. 
The later-appearing roX2-DCC, however, brings about a more efficient process of long-range 
DCC spreading onto the entire chromosome and/or more competent DCC in terms of 
hyperacetylation activity. Efficient spreading of DCC may also just be a product of roX 
abundance, whereby transcription of roX2 in addition to roX1 RNAs leads to greater number 
of associations between RNA and protein components of the complex, and therefore, more 
DCC are available to coat the chromosome.  
The structure of MOF has been well characterized and, in addition to its HAT domain 
responsible for the deposition of H4K16ac, it carries a chromo barrel domain (CBD) (213). 
Unlike other CDs, such as that of MSL3 which binds H3K36me3, MOF’s CBD lacks critical 
aromatic cage residues and thus is unable to bind methylated histones (213). Instead, it has 
been shown that MOF interacts with nucleic acids through the CBD with high preference of 
RNA over DNA in vitro and in vivo (214). Mutation or deletion of CBD leads to loss of roX 
RNA binding (214), which explains the loss of MOF recruitment in the absence of MLE (215) 
and loss of MOF association with the X upon RNAse treatment (214). It is appealing to think 
that maybe roX RNAs take part in the recruitment and stable association of MOF to the DCC 
and also induces MOF activity and in turn that of DCC.  
Positive effects of an interaction between a reader domain and nucleic acids on the protein 
or an associated complex have been reported for other CD-containing proteins such as Mi-2, 
an ATP-dependent chromatin remodeler, and Chromoboxes (CBXs), members of the 
Polycomb repressive complex 1 (PRC1). Loss of Mi-2’s CD leads to deficit DNA binding, 
decreased ATPase activity and impaired nucleosome sliding, while repressive activity of the 
PRC1 complex relies on RNA binding by hCBX7’s CD (216,217). It has also been shown that 
enhancer RNAs stimulate the activity of histone acetylation by CREB-binding protein (CBP) 
at enhancer sites in the mammalian system (218). Considering not much is described regarding 
functionality and structure differences between roX1 and roX2, it may just be the case that 
specific interaction of MOF and roX2 RNA in the context of DCC leads to functional 
consequences such as increased chromatin affinity, thus DCC binding stability, facilitated 
diffusion across the spatial landscape, thus spreading, or a change in conformation that affects 
the efficiency of the HAT, thus activity. 
Profiling of various MSL protein distribution of the same chromatin preparation of 
overnight embryos also exposed an interesting observation worth noting. Although X-enriched 
regions of MSL3, H3K36me3 and MOF closely resembled gene bodies, H4K16ac regions 
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extended far and beyond along the X chromosome, often times connecting multiple smaller 
regions into large ones encompassing many neighbouring gene bodies. H3K36me3 is thought 
to be the determining mark that recruits DCC to active genes along the X, however, discrepancy 
between H3K36me3 and H4K16ac distributions suggests that there may be other factors that 
contribute towards the spreading of acetylation (47,82,211,212,219,220). Recent experiments 
by Catherine Regnard saw a decrease in H3K36me3 upon knock-down of Set2, the HMT 
responsible for trimethylation of H3K36 from a dimethylated state. Nonetheless, distribution 
of MSL3 was largely unaffected. To investigate if there are other histone modification marks 
that also contribute towards DCC spreading, experiments using combinatorial modified 
histones to probe the recruitment of MOF that leads to H4K16ac spreading need to be 
performed. 
One such candidate that may be worth further investigation is the monomethylated state 
of H4K20. Conflicting reports have shown the correlation of H4K20me1 with positive as well 
as negative gene regulation (221). Although this rather suggests a context-dependent signalling, 
two studies have observed DCC protein interaction with H4K20me. Moore et al. reported that 
in vitro binding studies show preferential binding of MSL3’s CD to H4K20me1/2 and mutation 
to the binding cage of methylated lysine results in compromised survival of males (222). 
Furthermore, nucleic acid binding of the human MSL3 protein through its CD enhances 
H4K20me1 association (223). Several genome-wide distribution studies of H4K20me1 have 
been done in the context of female cells or mixed collection of embryos or larvae (224,225). It 
would be interesting to see how H4K20me1 is distributed in male population of cells. 
7.3.3 Dose imbalance of developmental genes 
Our study revealed that genes with the most variability in expression through the first 12 
hours of development are rather farther away from sites upon which DCC interacts favourably 
(210). Therefore, it is attractive to posit that developmental genes are less dependent on DC 
mechanism. Several reasons could be attributed to this; either their expression is well buffered 
in that minimal amount of transcription is sufficient, the product of these genes function like a 
switch in a dose-independent manner, or dosage-compensated developmental genes are 
required later in embryogenesis that is outside of our study window. Additionally, cell-type 
specific expression can be dominated by more abundant, ubiquitous expression of genes, and 
is technically challenging to determine in such heterogenous setting. 
A single embryo transcriptomic study by Lott et al. reported that many X-linked genes are 
equally expressed in male and female embryos at the onset of ZGA and indeed this list of genes 
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includes several key developmental regulators, such as giant (gt), brinker (brk), buttonhead 
(btd), and short gastrulation (sog) (22). Although the timepoints chosen by Lott et al. do not 
overlap with ours (210), the two transcriptomic studies complement one another in that both 
observe an X bias in maternally deposited genes. This may as well be a manifestation of a 
safety measure set in place to anticipate a possible deficit of X-linked genes, which are 
especially important for development at this early stage (22,226). As a matter of fact, the four 
genes mentioned above are expressed highest during the first 4 hrs ael as shown in in situ RNA 
studies of the Berkeley Drosophila Genome Project (227-230). Lott et al. also observed that 
the single X chromosome in the male organism expresses more transcripts than either one of 
the two X chromosomes in the female (22). Nevertheless, the total male transcript is still less 
than the female and requires compensation (22). They argue that a non-canonical pathway must 
have taken place prior to the canonical MSL-mediated dosage compensation that is very much 
in line with our observation, a 2-fold difference is never seen between male and female 
transcripts upon activation of the zygotic genome and the most bias observed is an average of 
1.2-fold expression in the female (210). It is then crucial to acknowledge that reaching a 
balanced state of expression is not achieved through a single mechanism, but relies on multiple 
factors that in parallel activate and also fine-tune the extent of hypertranscription not only on 
a general and nonspecific level but also on a gene-by-gene specific scenario (231). 
7.3.4 Are DCC, or any of its members, active on autosomes? 
MOF is the main HAT of H4K16ac (59,73-75). It also participates in another complex, the 
Non-Specific-Lethal (NSL). Previous reports have shown that in the context of NSL, MOF 
interacts with MBD-R2, a Zinc-finger transcription factor, and localizes to 5’ ends of gene 
bodies, specifically around promoters to mediate nucleosomal organization around TSSs 
(232,233). As the name suggests, the NSL complex is not specific towards any one sex as its 
disruption is lethal in both male and female (204). Furthermore, the complex functions in 
transcriptional regulation of housekeeping genes and is evolutionary conserved (234,235). 
Interestingly, MOF is highly X-enriched in our study and autosomal promoter peaks are rather 
negligible, in contrast to previous characterization of the protein (85,86) (210). Contrastingly, 
fairly even genome-wide distribution of H4K16ac regions emerge in the embryo dataset, 
although they are much larger on the X chromosome. It remains to be determined whether 
discrepancy of distribution is due to technical biases. 
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Recent published chromatin immunoprecipitation data of MSL2 appeared to suggest 
interaction of MSL2 with autosomes that have not been observed previously (236). In the study, 
flag-tagged transgene of msl-2, whose expression is driven by tub-Gal4:UAS system was 
generated, and MNase ChIP-seq was performed on L3 larvae. MSL2 peaks were found both in 
male and female at autosomal promoters of developmental genes, which they claimed have 
never been observed before due to the use of embryonic cell lines that do not express these 
developmental regulatory genes (236). Binding of MSL2 occurred specifically close to 
autosomal dosage-sensitive genes to evoke a gene-by-gene dosage compensation mechanism 
(236). Although they claimed that their msl-2 transgene was expressed to the same level as the 
endogenous msl-2, such observation could arise due to the differential experimental design and 
subsequent analysis. Roughly 150 autosomal peaks of MSL2 were also observed in developing 
embryos, although many of them were disregarded as functional binding due to lack of 
chromatin interaction (Fig. 27B-C) (210). Nevertheless, this number is already much less than 
the 1684 peaks reported by Valsecchi et al. (236). The msl-2 transgene lacked UTR and intron 
sequences, which are targets of Sxl in its negative regulation of the MSL2 (236). Thus, the 
female system was pushed to express MSL2 even in the presence of Sxl. The need for MSL2 
to regulate developmental genes at such a late stage is inconsistent with the lack of MSL2 
expression in female and their lethality when MSL2 is ectopically expressed (54-56).  
7.3.5 Technical differences: ChIP-seq  ChIP-seq? 
Common to many ChIP protocols is the inclusion of formaldehyde crosslinking prior to 
chromatin solubilization. The small size of formaldehyde creates covalent linkages between 
amine groups that are ~2 Å apart (237). As these reactive groups can be part of an amino acid 
or a nucleobase, formaldehyde can capture nucleic acid-protein as well as protein-protein 
interactions that are in close proximity, but will not distinguish them from two molecules that 
are near each other but do not interact or any transient non-specific binding for that matter. At 
the same time, true interaction may be missed in over-crosslinking condition as it is deleterious 
to the solubilization of chromatin. This is a bias of crosslinking that is unavoidable; 
alternatively, ChIP protocols can be done under native conditions without crosslinking and 
gives much greater signal to noise ratio in cases where chromatin association is maintained. 
Whereas stable interactions and chromatin complexes are well preserved under these 
conditions, weaker and low abundant interactions, may not withstand subsequent steps of 
isolation. As MSL2 is rather difficult to work with, all genome-wide studies of DCC 
distribution were done under crosslinked conditions. 
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High shearing is commonly done to solubilize material for further assays. Past experiments 
to portray DCC generally rely on this to solubilize chromatin-bound proteins for ChIP 
(85,86,91). Recent results, however, have rather pointed towards MNase digestion as the better 
method to preserve interactions, especially for sensitive proteins such as MSL2 (210). 
Differences in observation clearly suggest that the various methods to probe chromatin context 
depict distinct facets of dynamic biological processes. Sonication increases the efficiency of 
immunoprecipitation by ridding of non-specific and retaining the strongest interaction in the 
soluble chromatin. Unfortunately, this method of solubilization fails proteins that are easily 
destroyed and/or take part in transient bindings. Increased shearing has the potential to also 
expose hidden epitopes and may present, with the increased sensitivity, binding patterns that 
are discrepant with MNase digestion (97). MNase digestion enables the portrayal of weaker 
interactions that may be lost through harsher, mechanical solubilization methods, but it usually 
results in worse signal to noise ratio (189). Another concern of the MNase digest is the 
possibility of bias introduction as the MNase enzyme has a sequence preference and relies on 
accessibility of DNA, thus chromatin structure, in its function to cut (188). Nonetheless, a 
recent study by Baldi et al., makes the argument that the latter is likely to be insignificant, 
whereby profiles from MNase-digested chromatin resemble that of MNase-digested gDNA and 
genome coverage is rather independent of digestion degree (238). Additionally, accessibility 
of chromatin probed via MNase-seq in human cells showed no differences in euchromatin and 
heterochromatin (239). Therefore, with the possibility to perform paired-end sequencing, 
MNase digestion provides an additional advantage in painting a genome-wide picture of DNA 
binders, as the various types of interaction, i.e. DNA-protein and protein-protein, can be 
deduced and allow for the study of larger assemblies indirectly bound to chromatin. 
As genome-wide studies are becoming more and more prevalent in the attempt to better 
understand chromatin dynamics and higher order structures, it becomes imperative that 
appropriate methods and conditions are chosen. A recent development of the Cleavage Under 
Targets and Release Using Nuclease (CUT&RUN) method developed by the lab of Steven 
Henikoff presents another tool that can better probe the native state of chromatin (240). 
CUT&RUN profiles chromatin landscape by using the specificity of an antibody to target 
MNase cleavage to release protein-DNA complexes from intact nuclei. Combined with paired-
end DNA sequencing, CUT&RUN has been used to successfully create profiles of transcription 
factors and histone proteins without crosslinking, although if needed, it can be included 
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(240,241). It may be worthwhile to look into DCC distribution through this method, especially 
in the case of MSL2, which has been one of the most fastidious proteins to work with. 
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